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ABSTRACT 
 
Peter Matthew Thompson: The Structural and Functional Consequences of the Interaction 
of the Vinculin Tail Domain with F-actin and PIP2 
(Under the direction of Sharon L. Campbell) 
 
Vinculin is an essential, highly-conserved eukaryotic scaffolding protein. It localizes 
to focal adhesions and adherens juctions, where it assists in physically linking the actin 
cytoskeleton to the adhesive structure. Loss of vinculin causes embryonic lethality with 
observable cardiovascular and neural defects. Vinculin is comprised of three domains: a 
large helical head domain, an unstructured proline-rich linker, and a helical tail. Vinculin 
functions as a scaffold, alternating between an autoinhibited conformation in which it 
cannot bind ligands, and an open conformation in which it is free to bind ligands at all three 
domains. 
The tail domain binds a variety of ligands, two of which are F-actin and 
phosphatidylinositol 4,5-bisphosphate (PIP2). Both interactions lack good structural models, 
which has hindered the development of tools to understand the specific biological functions 
these interactions play. Using a variety of biochemical and biophysical techniques and tools, 
we have developed new structural models for these interactions. The PIP2 model shows how 
the basic residues in helices 1 and 2 specifically recognize PIP2, while basic residues on helix 
3 are responsible for membrane association.  
Actin-binding, conversely, is driven by a hydrophobic patch on helix 4. The 
application of cryo-electron microscopy has also revealed some of the conformational 
changes that take place in the tail domain when it binds F-actin: helix 4 straightens and helix 
1 is discharged from the helix bundle. 
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Additionally, we characterize the backbone dynamics of Vt by nuclear magnetic 
resonance. These experiments reveal the presence of μs-ms motions that reside where the C-
terminal arm interacts with the helix bundle. These motions may be involved in the 
conformational change that takes place upon actin binding.
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Chapter 1: Introduction and Background 
Introduction 
Vinculin is an essential scaffolding protein, ubiquitously expressed in higher 
eukaryotes, that localizes to focal adhesions (FAs) and adherens junctions (AJs). Initially 
discovered in chicken gizzard in 1979 (1), vinculin is large (117 kDa) and highly conserved (2, 
3). Vinculin plays a key role in signaling at sites of adhesion, and has been implicated in 
regulating cell morphology, cell migration (4), cell stiffness (5, 6), adhesion strength (7), 
adhesion turnover, and adhesion morphology (8, 9). It regulates these processes by binding 
to multiple biomolecules, creating physical linkages between proteins at precise times and in 
precise subdomains of focal adhesions and adherens junctions. Vinculin’s structure makes it 
uniquely suited for this role. 
Vinculin contains two distinct domains: an N-terminal head domain (Vh) and a C-
terminal tail domain (Vt), which are connected by a proline-rich linker (Figure 1.1). Vh and 
Vt are alpha-helical in nature, while the proline-rich linker lacks defined structure (2). Vh 
can be further subdivided into four subdomains (D1-D4), each of which is made up of one or 
two helix bundles. Vt is a five-helix bundle with an N-terminal strap and a C-terminal 
extension (10). While neither the strap or C-terminal extension have a defined secondary 
structure, they make interactions with the helix bundle and are thought to be somewhat 
ordered. Each vinculin domain is capable of binding to a variety of ligands, each with unique 
cellular consequences. Vh can bind talin (11), α-catenin (12, 13), α-actinin (14), and MAPK 
(15). The proline-rich linker houses binding sites for p130CAS (16), vasodilator-stimulated 
phosphoprotein (VASP) (17), ponsin/CAP (18), vinexin α/β (19), and the Arp2/3 complex 
(20). Vt interacts with filamentous actin (F-actin) (21), paxillin (22), raver1 (23), 
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phosphatidylinositol-4,5-bisphosphate (PIP2) (3), Hic-5 (24), protein kinase C alpha (PKCα) 
(25), tyrosine-protein kinase CSK (src) (26), and α-synemin (27). 
In addition to the ligands mentioned above, Vh and Vt interact at high affinity (11, 28) 
in the absence of ligands (2, 28). This conformation is referred to as the “inactive” 
conformation, as vinculin is unable to bind ligands in this state. However, vinculin becomes 
activated by binding multiple ligands, which compete with autoinhibitory contacts between 
Vh and Vt (29), forming the “active” conformation (Figure 1.2). This exposes even more 
binding sites on vinculin, allowing binding of more biomolecules. In addition to regulation of 
vinculin conformation by the presence or absence of ligands, phosphorylation and other 
post-translational modifications may also regulate the equilibrium between the active and 
inactive conformations (30, 31). 
While much is known about what ligands bind to vinculin, less is known about how 
these ligands bind, especially to Vt. As of the writing of this manuscript, there are co-
structures in the PDB for vinculin with talin (32), α-actinin (33), α-catenin (34), ponsin/CAP 
(35), vinexin (36), two bacterial ligands that exploit vinculin (from Shigella flexneri and 
Rickettsia rickettsii) (37, 38), raver1 (39), and PIP2 (40). Because the Vt is able to bind to so 
many ligands and because these binding sites are poorly characterized, it has been difficult 
to study the cellular consequences of these specific interactions. Frequently, multiple 
mutations (41, 42) or large deletions (7, 42) are made to vinculin constructs in cells, which 
result in the unintended consequences of disrupting Vt structure and/or disrupting multiple 
Vt:ligand interactions (43). Part of the difficulty in defining ligand-binding sites on Vt at 
high resolution comes from the experimental difficulties presented by PIP2 and F-actin, 
which do not lend themselves to crystallization or easy study by NMR. However, recent 
advances in negative-stain and cryo-electron microscopies, nanodisc preparation, and in 
computational modeling have provided new ways to identify and characterize these 
structures and binding surfaces.  
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Focal adhesion architecture and signaling 
While vinculin is localized to both FAs and AJs and has essential roles in each 
structure, its roles at FAs have been better characterized, primarily due to the development 
of vinculin-null fibroblasts and their ease of use. For this reason, much of the work described 
in this thesis has been conducted in collaboration with cell biologists who study FAs, and a 
brief description of FAs is provided. 
FAs are large (up to 200 nm in length (44, 45)), multi-protein substructures in cells 
that are responsible for mechanically linking the cytoskeleton to the extracellular matrix 
(ECM). Of the proteins that comprise FAs, the vast majority are cytsoplasmic, save for the 
protein integrin, a transmembrane protein. Integrins are receptors, comprised of an α and β 
chain, that physically contact fibronectin, collagen, vitronectin, or other ligands present in 
the ECM (46-48). Syndecan 4 (49) is another transmembrane protein that has been 
identified in FAs, though its role seems to be less integral. 
The cytoplasmic side of FAs is much larger and contains a greater variety of proteins. 
Integrins span the plasma membrane, and so part of the protein does reside in the 
cytoplasm. These tails change conformation upon binding (outside-in signaling), and can 
also receive internal signals that are passed to the integrin receptors (inside-out signaling) 
(50). The intracellular integrin tail domain can bind to talin, another protein localized to 
focal adhesions. Talin, like vinculin, is a scaffolding protein that exists in an autoinhibited 
state (51). It unfurls to bind actin, linking the actin cytoskeleton to integrin, though it does 
this somewhat poorly, as its actin-binding affinity is somewhat weak (52). The unfurling of 
talin exposes multiple vinculin binding sites, and it is thought that the recruitment of 
vinculin by talin stabilizes the actin linkage to integrins (53). 
Like vinculin, paxillin is a scaffolding protein that localizes to FAs. Much less is known 
about paxillin, though it has a number of phosphorylation sites that mediate its interactions 
with a variety of proteins (54). However, unlike vinculin and talin, which physically span 
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from the plasma membrane to the actin cytoskeleton, paxillin is found very near the 
membrane (55). A variety of other proteins are localized to FAs. VASP, profilin, Arp2, and 
Arp3 are involved in promoting actin polymerization and branching, and have all been 
identified at FAs.  
Many of these proteins are regulated by phosphorylation. Indeed, a common way to 
visualize FAs in cells is to use a phosphotyrosine antibody coupled to a fluorophore (56). 
Vinculin, paxillin, and focal adhesion kinase (FAK) are all targets of tyrosine kinases. FAK, 
src, csk, and fyn are the primary tyrosine kinases responsible for tyrosine phosphorylation at 
FAs (57). Additionally, PKCα, a serine kinase, is a key FA component and its ability to 
phosphorylate Vt is dependent on PIP2 signaling (58). PKCα-mediated phosphorylation of 
vinculin has been implicated in vinculin activation and subsequent FA maturation (30), 
though direct validation of this mechanism has remained elusive. 
All of this organization and signaling is designed to regulate attachment to the actin 
cytoskeleton, which resides approximately 80+ nm from the plasma membrane (55). While 
talin and vinculin are responsible for physically linking actin to the FA, other proteins can 
bind actin and crosslink individual filaments, such as α-actinin (59). Vinculin likely 
crosslinks filaments right as they reach the FA, while α-actinin continues to crosslink 
filaments further from the FA (55). These crosslinked filaments form stress fibers, through 
which the majority of the contractile forces are initiated. This contractility is generated by 
myosin II and is regulated by the Rho family of small GTPases (60). 
Metavinculin is a tissue-specific splice variant of vinculin 
Transcripts of VCL are alternatively spliced in muscle tissues, leading to expression of 
both vinculin and metavinculin (150 kDa) (61). Both isoforms are localized to the cell 
membrane, the I-band in the sarcomere, and to intercalated discs (62). Metavinculin 
transcripts contain an extra exon (exon 19) that codes for a 68-residue insert in the tail 
domain. While vinculin is highly conserved across species, exon 19 is much less conserved 
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(63). This extra exon codes for residues between helices 1 and 2 in the Vt primary sequence 
and confers unique functions to metavinculin (64). Structurally, these new residues replace 
the residues 879-915, which code for the N-terminal strap and helix 1 in Vt (65) (Figure 
1.3). Functionally, this helix swap confers higher affinity for raver1 (23) and weaker affinity 
for PIP2 (66) in metavinculin compared to vinculin. Metavinculin interactions with F-actin 
appear more complex. The tail domain of metavinculin can sever actin filaments, though this 
function appears to be regulated by the proline-rich linker an the head domain and such 
activity has not been observed in vivo (67). Metavinculin tail also appears to be less a less-
capable actin crosslinking protein (68), though these results require further study, as the 
potential actin-severing properties may have skewed crosslinking analyses. 
While the immediate cellular consequences of these structural and biochemical 
differences requires further study, it is currently believed that metavinculin is specialized for 
mechanotransduction, as its expression levels positively correlate with the force exerted on 
cells (44, 66, 69). These levels are high in the smooth muscle of the aorta and uterus (66), 
tissues that experience substantial amounts of force. However, when smooth muscle cells 
from human aorta (44, 62, 70) and chicken gizzard (71) are subcultured, they exhibit a 
marked decrease in metavinculin expression levels. This occurs as they are cultured, during 
which they experience weaker forces and tension than in vivo. This suggests that there is a 
feedback mechanism between the forces a cell experiences and the amount of metavinculin it 
expresses. 
Vinculin in health and disease 
Because of its roles in regulating adhesions, vinculin is required for embryogenesis and 
cardiovascular development, processes that require tight regulation of cell movement and 
cellular forces. Vinculin null mice fail to develop properly, ceasing to grow after embryonic 
day 10, exhibiting neural and cardiac defects (8). Mice with conditional vinculin expression 
fail to survive more than a few weeks without vinculin, dying from ventricular tachycardia or 
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dilated cardiomyopathy (72). Mice with hemizygous expression of vinculin fare better under 
normal conditions but will expire weeks after undergoing cardiac pressure loading (73). 
Additionally, mutations in metavinculin are associated with the development of 
cardiomyopathies in humans (65, 68, 74-77). These mutations are believed to disrupt the 
interactions with of metavinculin with F-actin (68), though other possible mechanisms for 
these mutants have not been thoroughly explored.  
With a role in cell migration, many have hypothesized that vinculin plays a significant 
role in cancer, specifically in metastasis (78). However, a clear link has been difficult to 
establish. The first clues came from vinculin-null murine embryonic fibroblasts, which are 
resistant to apoptosis and anoikis (15) and exhibit increased motility, weakened adherence, 
and a rounded morphology (4, 9). These results suggest that vinculin is a tumor suppressor. 
Indeed, studies have correlated lower expression levels in both transformed cell lines (79) 
and in tumors (80) with a more tumorigenic phenotype. Activation of vinculin in M21 
melanoma cells conferred greater susceptibility to chemotherapies (81). However, greater 
vinculin expression was found in castration-resistant prostate tumors, while decreased 
expression was observed in benign hyperplasias (82). Additionally, a transcriptome study of 
colon cancer showed that, for primary tumors and metastases, vinculin expression is 
increased, while metavinculin expression is decreased (83). Another study showed an 
increase in vinculin expression in lung cancer metastases (84). Increased vinculin 
localization to FAs in stiffer substrates correlates with increased phosphoinositide 3-kinase 
(PI3K)/protein kinase B (Akt) signaling in mammary tissue, suggesting a similar trend for 
breast cancer metastases (85). These conflicting reports speak both to the diversity of 
mechanisms that drive different cancers and to the complexity of vinculin signaling. 
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Figure 1.1. The structure of vinculin. 
The crystal structure of chicken vinculin (PDB code 1ST6) is shown in a cartoon 
representation. The vinculin head domain is shown in cyan, the proline-rich linker in purple, 
and the vinculin tail domain (Vt) in sand. 
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Figure 1.2. Diagram of vinculin activation 
In the absence of ligands, vinculin exists in an autoinhibited conformation, mediated 
by a strong interaction between the head and tail domains. Activation of vinculin requires 
the presence of both a head ligand, such as talin, and a tail ligand, such as F-actin. When 
both ligands are available, the head domain and tail domain release their autoinhibitory 
interaction and bind to their respective ligands. This conformational change allows for 
binding of additional ligands on vinculin surfaces protected by the autoinhibited 
conformation. 
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Figure 1.3. Comparison of vinculin and metavinculin tails. 
The overlaid structures of human Vt and metavinculin tail domains (structures used 
are from PDB code 1RKE and Rangarajan et al. (65), respectively). Vinculin is shown in sand 
and metavinculin in lavender. The structures are very similar, especially in the helix bundle. 
Below is an alignment of the metavinculin 68-residue insert with vinculin residues 848 to 
915. The second half of the insert shows high sequence similarity and homology to the 
vinculin sequence that forms the N-terminal strap and helix 1. 
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Chapter 2: Characterization of the Interaction Between the Vinculin 
Tail Domain and PIP2-containing Membranes 
Introduction 
 Vinculin tail (Vt) can bind to many different ligands, including acidic phospholipids 
(86), specifically phosphatidylinositol 4,5-bisphosphate (PIP2) (43). This interaction may 
activate vinculin by disrupting the vinculin head:tail interaction (10, 32, 87). PIP2 is an 
important signaling lipid for numerous cellular processes, including membrane ruffle 
formation (88), exocytosis (89), and phagocytosis (90). In the case of focal adhesions (FAs), 
PIP2 is generated by phosphatidylinositol phosphate kinase type 1 gamma (PIPKIγ) (91), 
which is recruited to focal adhesions by talin (92, 93). Talin recruits vinculin, meaning that 
vinculin colocalizes with and PIP2, which regulates the interaction of vinculin with talin (11, 
94). PIPKIγ regulates FA dynamics (95, 96), is required for FA formation (97), and is 
thought to be involved in recruitment and activation of vinculin at FAs (96, 98). While much 
is known about the general role of PIP2 at FAs, the consequences of the vinculin:PIP2 
interaction are much less understood, in part because of the lack of understanding for how 
Vt binds PIP2. The interaction has been implicated in cell spreading, cell migration, FA 
turnover, and force transduction (41, 42, 99), though the vinculin constructs used in these 
studies may not be selective in their disruption of PIP2-binding. 
 When the structure of Vt was first solved by X-ray crystallography, two surfaces on Vt 
were identified that contain a high concentration of basic residues: the basic ladder and the 
basic collar (Figure 2.1) (10). These regions were predicted to be potential binding sites for 
acidic phospholipids, but defining which site drives lipid binding has been quite difficult. 
Different labs have provided evidence for a loss in PIP2 binding by mutating the basic collar 
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(2, 58, 99), the basic ladder (41), or deleting the C-terminus (41, 42, 58, 99, 100). Other 
groups have expressed peptide fragments of Vt and found that the basic ladder (3) or the C-
terminus (101) are sufficient for PIP2 binding. 
However, the use of multiple mutations, deletions, and fragments of Vt likely alter its 
structure and perturb other Vt functions (43). Hence, their use in studying the vinculin:PIP2 
interaction in cells provides potentially misleading results. For example, the use of two 
separate vinculin variants with reported PIP2 defects of comparable severity, 
vinculinK952Q/K956Q/R963Q/R966Q and vinculin R1060Q/K1061Q, resulted in two 
distinct cellular phenotypes; the double mutant disrupted the ability of the cells to exert 
force on their substrate by 50%, the quadruple mutant did not (42). These disparate and 
confusing results result largely from the lack of a good structural model for the interaction of 
Vt with PIP2 and the use of poorly characterized PIP2-defective vinculin variants. This 
problem is not unique to the interaction of vinculin with PIP2, as similar approaches have 
been used to study the interaction of vinculin with actin (Chapter 3). 
Recently, a crystal structure of a Vt mutant bound to a soluble, short-chain PIP2 was 
solved by Chinthalapudi et al., providing the first structural model for how PIP2 binds to Vt 
(PDB file 4PR9) (40). In the crystal structure, Vt R1060A forms trimers upon associating 
with PIP2. Two of the Vt molecules recognize the PIP2 headgroup via residues in the basic 
collar whereas the third Vt molecule interacts with the PIP2 headgroup through residues 
K944 and R945. To test their model, mutations were made to residues in the basic collar (Vt 
K1061Q) or the basic ladder (K944Q/R945Q), and were found to disrupt PIP2-binding by 
lipid co-sedimentation. The authors posit that these mutations support their model for how 
Vt binds PIP2 and that their model accurately depicts the oligomerization state of Vt upon 
binding to PIP2. Vt has been shown, by crosslinking, to dimerize and trimerize in the 
presence of PIP2- or phosphatidylserine (PS)-containing liposomes (10, 43, 102). However, 
while the crystal structure does provide possible models for Vt dimers and trimers linked by 
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PIP2, these models do not explain how Vt would insert into a lipid bilayer (3). Additionally, 
vinculin-null mouse embryonic fibroblasts expressing vinculin showed phenotypes effects 
for two different vinculin constructs with weak PIP2 binding. The K944Q/R945Q double 
mutation, as evaluated by fluorescent recovery after photobleaching (FRAP), prevents 
exchange of vinculin at FAs, while the K1061Q mutant only mildly disrupts exchange of 
vinculin at FAs. We applied biochemical and computation methods to this system to address 
these discrepancies. 
Materials and Methods 
Expression and purification of Vt 
 Vt constructs expression constructs were a gift from Susan Craig. The pET15b Vt 
expression vector encoded a His-tag followed by a thrombin cleavage site and then chicken 
Vt residues 884-1066. Vt was expressed by transforming BL21 E. coli with the vector, 
growing to an OD at 600 nm of 0.6, dropping the temperature to 18 C°, and inducing 
expression with 0.25 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were grown 
overnight, centrifuged, resuspended in lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 5 
mM imidazole, 5 mM β-mercaptoethanol), and frozen until sonication. Vinculin tail protein 
was purified as previously described (43).  
Lipid co-sedimentation assays 
Vt binding to PIP2 was evaluated by lipid co-sedimentation assays using small, 
unilamellar vesicles (SUVs) as reported (43, 103). SUVs were composed of 250 µg lipid 
mixture, with the reported PIP2% and a 3:1:1 ratio of phosphatidylethanolamine to 
phosphatidylcholine to PS and/or PIP2. The lipids (Avanti Polar Lipids, Alabaster, AL, USA) 
were resuspended by vortexing in the lipid co-sedimentation buffer (40 mM MES pH 6.0, 
150 mM NaCl, and 2 mM dithiotheitol (DTT)) and subsequently extruded in a mini-extruder 
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(Avanti Polar Lipids) to produce the SUVs. Relative protein amounts were quantified using 
ImageJ (104). 
Binding to PS was evaluated similarly, with the only difference being the ratio of lipids 
used. When assembling SUVs, the reported percentage of PS was used, and the remaining 
lipids were a 3:1 mixture of phoshphatidlyethanolamine to phosphatidylcholine. 
Actin co-sedimentation assays 
 Actin co-sedimentation assays for both actin binding and actin crosslinking 
(bundling) properties of Vt were performed as previously reported (6, 103). 
Mutagenesis of DNA constructs 
 Vt variants were generated using QuikChange site-directed mutagenesis (Stratagene) 
and sequences were verified by DNA sequencing (Genewiz). 
Computational modeling 
 Modeling of the interaction of the headgroup of PIP2 with Vt (residues 896-1055) was 
performed with MedusaDock (105, 106). MedusaDock utilizes a library of rotamers for the 
sidechains of Vt and a separate library for rotamers of the PIP2 headgroup. Docking 
simulations are performed using these libraries, while the secondary structure remains 
fixed, and the results are ranked by MedusaScore. The lowest energy pose is reported. 
Modeling of the interaction of the full PIP2 molecule, 1-stearoyl-2-arachidonoyl-sn-
glycero-3-phospho-(1'-myo-inositol-4',5'-bisphosphate), with Vt in the absence of a lipid 
bilayer was performed with discrete molecular dynamics (DMD) simulations (107-109). The 
initial docking pose was taken from the MedusaDock simulations. In these all-atom DMD 
simulations, Gō constraints were used to maintain intramolecular Cβ/Cα contacts between 
Vt residues during the simulation. These constraints were applied for all residues in Vt or 
only residues in alpha helices in different simulations. The Gō constraints limit the potential 
for Vt unfolding while the PIP2 is allowed to sample the protein surface. This combination 
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allows for greater sampling of potential Vt:PIP2 interactions while maintaining the structural 
integrity of Vt. The assumption that Vt retains its fold upon binding to PIP2 is supported by 
the lack of large conformational changes in the helix bundle in the crystal structure of Vt 
bound to a short-chain PIP2 (40). 
Modeling of the interaction of PIP2 within a lipid bilayer was performed using all-
atom, explicit solvent molecular dynamics simulations. A lipid bilayer of 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) with a single PIP2 molecule was generated, and 
an initial pose of Vt (residues 896-1055) bound to PIP2 using the model generated from 
MedusaDock. Simulations were done with GROMACS (110) using a CHARMM27 force field 
(111) and performed for 150 nanoseconds. A control experiment with a bilayer consisting 
entirely of POPC was also conducted.  
Circular dichroism spectroscopy 
 Circular dichroism (CD) spectra were collected as reported (43). Spectra were 
collected on a Jasco J-815 CD Spectrometer at 25°C in 10 mM potassium phosphate, pH 7.5, 
50 mM Na2SO4, and 1 mM DTT. For spectral scans, Vt was concentrated to 5 μM for 260-190 
or 450 μM for 350-250 nm. For thermal melts, 5 μM Vt was used and ellipticity at 222 nm 
was monitored as the temperature was increased from 25 C° to 95 C° at a rate of 2 C°min-1. 
Results 
Computational modeling predicts distinct roles for the basic collar and basic ladder 
 To develop a structural understanding for how PIP2 is bound by Vt, modeling of the 
interaction of PIP2 with Vt was performed in collaboration with the Dokholyan Lab at UNC 
Chapel Hill. The headgroup of PIP2, D-inositol 4,5-bisphosphate, was docked to Vt residues 
895-1065 using MedusaDock (105, 106). The N-terminal strap was omitted from Vt for 
docking. It is likely that the N-terminal strap is displaced when Vt binds to PIP2 as removal 
of the N-terminal strap increases binding to PIP2 (43), suggesting that this deletion is not 
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unreasonable. MedusaDock identified the basic collar, specifically residues R910, K915, 
K924, and R925, as the site on Vt with the highest affinity for the PIP2 headgroup. R910 
interacted primarily with the hydroxyl of C4, K915 with the hydroxyl of C6 (which would 
place it near the phosphoryl group on C1 in the full PIP2 molecule), K924 with the hydroxyl 
of C5, and R925 with the phosphoryl group on C4 (Figure 2.2). This finding is in agreement 
with the general geometry of the basic collar compared to the basic ladder, in which the 
positive charges within the basic collar are clustered in a smaller surface area more 
compatible with headgroup coordination relative to the basic ladder.  
 Next, DMD simulations (107-109) were performed with a complete PIP2 molecule, 1-
stearoyl-2-arachidonoyl-sn-glycero-3-phospho-(1'-myo-inositol-4',5'-bisphosphate). 
Simulating the interaction with the entire PIP2 molecule was the logical next step from the 
initial simulations with just the inositol headgroup. Simulations were performed using Gō 
constraints on Cb/Ca contacts (with the interaction square-well depth 0.5ε, where ε is the 
DMD energy unit (108, 112)) for all residues in Vt (residues 896-1065) or Gō constraints 
only for residues in alpha-helices (using Vt constructs 896-1065 or 896-1059). After 
selecting 2000 snapshots with a binding energy less than -10 kcal/mol (105), the residues in 
contact with PIP2 were tallied (Figure 2.2). In all cases, the contacts at the basic collar 
remained high. When using Gō constraints only for helical residues, some contacts were 
observed at the basic ladder, though contacts at the basic collar were more frequent. 
 While both MedusaDock and DMD simulations suggested that the basic collar was 
the primary determinant for PIP2 headgroup recognition, these simulations were done only 
with the PIP2 molecule or headgroup, not in the context of a lipid bilayer. To better mimic 
the physiological interaction at the membrane, all-atom, explicit solvent molecular dynamics 
simulations of Vt bound to PIP2 in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) bilayer were conducted. The initial pose had Vt (residues 896-1055) bound to PIP2 
in an orientation that best matched the docking pose. The Vt helix bundle was oriented 
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roughly parallel to the lipid bilayer at the start of the simulation. However, by the end of the 
simulation, the side chains of K944, R945, K952, and K956, all in helix 3, show lipid 
interactions resulting in insertion in the lipid bilayer (Figure 2.2). Throughout the 
simulation, the basic collar maintained contacts with PIP2. A control simulation was 
performed without PIP2, and no specific interaction with the POPC membrane was observed. 
Results from these simulations suggest that, while the basic collar is responsible for PIP2 
recognition, the basic ladder is required for insertion into and full association with lipid 
bilayers.  
A common Vt variant deficient in PIP2-binding is a poor actin crosslinker 
The vinculin variant, LD-CT (vinculin R1060Q/K1061Q), has been used in a number of 
studies as a lipid-binding deficient vinculin construct (41, 42, 58). While Ziegler et al. (58) 
observed no defects in actin binding or bundling for Vt LD-CT, Diez et al. reported that this 
construct may have “impaired actin-vinculin binding” that would explain the lower strain 
energy cells generate when expressing vinculin Vt LD-CT (42). To address this controversy, 
we performed actin co-sedimentation assays with Vt LD-CT. High-speed co-sedimentation 
assays revealed that Vt LD-CT has no observable actin-binding defect (Figure 2.3). 
However, low-speed actin co-sedimentation assays show that Vt LD-CT is deficient in F-
actin crosslinking (Figure 2.3). These results further highlight the importance of the C-
terminus in actin crosslinking and the ability of vinculin to regulate mechanical force 
through actin crosslinking (6). This can explain the decreased strain energy seen by Diez et 
al. (42) as a consequence of the lost vinculin crosslinking function in vinculin LD-CT. 
Mutation of residues in the basic collar impairs binding to PIP2-containing liposomes and 
Vt dimerization 
While previous work has shown that mutations at the basic collar or the basic ladder of 
Vt decrease lipid binding, our molecular dynamics simulations suggested that the key 
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residues for PIP2 headgroup recognition are R910, K915, K924, and R925. The T6 construct 
(Vt T6) construct, reported by Cohen et al. (28), consists of a K924A/R925A double 
mutation. We measured the PIP2-binding activity of Vt T6 and the quadruple mutant 
R910A/K915A/K924A/R925A (Vt BC-4A) using a PIP2 co-sedimentation assay (43). While 
Vt T6 exhibited a modest decrease in binding to PIP2, with roughly half as much Vt binding 
at 5% PIP2 (Figure 2.4), Vt BC-4A showed an even greater drop in PIP2 binding, with a 6-
fold decrease in binding at 5% PIP2. Fitting the curves to a one-site binding model resulted 
in an approximate KD of 43 ± 12 μM for Vt, 191 ± 29 μM for Vt T6, and 551 ± 66 μM for Vt 
BC-4A. These findings suggest that the basic collar, specifically residues R910, K915, K924, 
and R925, plays a key role in PIP2 binding. 
To assess the viability of these variants as tools for study of a PIP2-specific defect in 
cells, the basic collar Vt variants were tested for their ability to bind F-actin and to dimerize 
to bundle F-actin. Using an actin co-sedimentation assay, no significant change in binding to 
F-actin for any basic collar Vt variant was observed (Figure 2.4). These results are not 
surprising, given that the basic collar is separate from the actin-binding surface of Vt. 
However, mutation of the basic collar did result in a significant decrease in the ability of Vt 
to bundle F-actin filaments, as measured by a low-speed co-sedimentation assay (Figure 
2.4). This decrease was not rescued by using the more conservative Vt variant, Vt BC-4Q 
(R910Q/K915Q/K924Q/R925Q) (Figure 2.5). 
Mutation of residues in the basic ladder impairs binding to PIP2-containing liposomes but 
not Vt dimerization 
 Since mutations to the basic collar disrupt the ability of Vt to bundle F-actin, vinculin 
variants at this site would be poor tools to study lipid-binding by vinculin in cells. Observed 
phenotypes could not be solely attributed to the loss of PIP2 binding. Previous work has 
shown that mutation of basic residues within helix 3 of Vt can also disrupt binding to PIP2-
containing liposomes (40, 41), suggesting that these residues may be good targets for 
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disrupting PIP2-binding. Three constructs were generated to test the importance of helix 3 in 
binding to PIP2-containing liposomes: Vt K944A/R945A (BL-2A), Vt K944A/R945A/K952A 
(BL-3A), and Vt K944A/R945A/K952A/K956A (BL-4A). These constructs all show 
decreased binding to PIP2-containing liposomes (Figure 2.6). Vt BL-4A exhibited the most 
severe defect, with an effective Kd 13-fold weaker than Vt WT. Vt BL-2A and Vt BL-3A have 
Kd values roughly 6.5-fold weaker than Vt WT.  
Actin binding and crosslinking activities for these variants were evaluated to test the 
specificity of the PIP2-binding defect. Vt BL-2A, Vt BL-3A, and Vt BL-4A do not have 
significantly different effective Kd values for binding actin (Figure 2.6). Additionally, slow 
speed actin co-sedimentation assays show that there is no significant difference in the ability 
of these variants to crosslink F-actin (Figure 2.6). These data, in conjunction with the lipid 
co-sedimentation data, support the use of these basic ladder variants in studying the 
biological function of the vinculin:PIP2 interaction. 
Mutations to the basic collar decrease Vt stability 
To evaluate potential alterations in Vt structure by mutations to the basic collar and 
basic ladder, CD data were collected. Far-UV data show a slight increase in helical secondary 
structure for Vt BL-4A (Figure 2.7). This increase in helical character may result from the 
K944A and R945A mutations, which may extend helix 3 by incorporating some of the helix 
2-helix 3 loop residues into helix 3. Near-UV CD data, which report on the packing of W912 
with W1058 and act as a proxy for tertiary structure, show that Vt BC-4Q and Vt BL-4A 
retain the packing interaction, as both peaks at 283 and 290 nm are maintained. Their 
signatures are slightly different, especially for Vt BL-4A, though, suggesting that the packing 
of W912 and W1058 has been somewhat altered. Thermal stability of Vt BC-4A, Vt BC-4Q, 
and Vt BL-4A was measured by monitoring CD at 222 nm as temperature increased (Figure 
2.7). After normalizing the data, subtracting buffer contributions, and fitting to a sigmoidal 
curve (Figure 2.7), the denaturation midpoint (Tm) was calculated (Table 2.1). Vt BC-4A 
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has a 10 C° decrease in Tm that is only partially rescued with the more conservative Vt BC-
4Q. Vt BL-4A is slightly more stable than Vt WT, but only by 2.2 C°. These results suggest 
that the basic collar, in addition to mediating Vt dimerization and actin crosslinking activity, 
is important for Vt stability. 
Mutation of residues in the basic ladder result in a larger defect in PS binding relative to 
mutation of residues in the basic collar 
 As mutations at both the basic collar and basic ladder impair Vt binding to PIP2-
containing liposomes, it is difficult to determine which site is responsible for PIP2 specificity 
by lipid co-sedimentation. Co-sedimentation experiments conducted with increasing 
amounts of PIP2 did not show a large difference in the ability of Vt BC-4Q or Vt BL-4A to 
bind PIP2-containing liposomes (Figure 2.8). However, since our computational modeling 
and biochemical data suggest that the basic ladder is responsible for insertion into the lipid 
membrane and the basic collar provides PIP2 headgroup specificity, but that both functions 
are important for lipid binding in our co-sedimentation assays, we tested the hypothesis that 
the basic ladder in critical for insertion by using lipid co-sedimentation assays with 
increasing concentrations of PS and no PIP2. While both Vt BC-4Q and Vt BL-4A bound PS-
containing liposomes weaker than Vt WT, Vt BC-4Q retained binding, with 15% of Vt BC-4Q 
bound when liposomes were 60% PS (Figure 2.8). Vt BL-4A, however, did not show 
significant binding, even at high levels of PS. These data suggest that the basic ladder 
residues K944, R948, K952, and K956 drive the non-specific interactions with negatively-
charged lipid membranes. Because mutations at the top of the basic ladder impair lipid 
association but do not impair actin interactions, these variants are reasonable tools to study 
the effect of lipid binding by vinculin in cells. 
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Discussion 
While it is known that vinculin binds PIP2 with high specificity (43) and facilitates 
membrane association (3), the biological role of this interaction remains unclear. The study 
of the vinculin:PIP2 interaction has been frustrated by a number of factors. The lack of a 
good structural model and seemingly contradictory biochemical data resulted in the use of 
vinculin variants with multiple ligand-binding defects, not solely PIP2 (41, 42, 99, 113, 114). 
The use of these tools has resulted in publication of seemingly contradictory data, even 
within the same manuscript (40, 42)! The recent structure from Chinthalapude et al. (PDB 
file 4PR9) provides a good start to developing a structural model of the interaction of 
vinculin with PIP2, but it falls short of explaining how this interaction takes place at a 
biological membrane (40). 
The biochemical data presented here are in agreement with those published by 
Chinthalapudi et al., who observed that mutating K944 and R945 or mutating K1061 weaken 
PIP2-binding activity by Vt (40). Both the basic collar and the basic ladder play important 
roles in binding to PIP2-containing membranes. However, while Chinthalapudi et al. 
attribute the effects of mutating K944 and R945 to the presence of a second PIP2-binding 
site for the PIP2 headgroup on Vt that also assists in oligomerization, our results suggest that 
these residues interact with the lipid bilayer in a PIP2-independent manner; the larger defect 
in binding to PS-containing liposomes and our computational model point to the role of 
these residues as critical for insertion into the plasma membrane. This interpretation of the 
biochemical data is further supported by previous work from Palmer et al. who found that, 
in solution, short-chain PIP2 binds non-specifically to Vt (43), supporting the notion that the 
native interaction of Vt with PIP2 requires the presence of a membrane. Because the 
structure generated by Chinthalapudi et al. was done in the absence of a membrane and with 
a R1060A mutation, some of the PIP2 contacts observed may be non-specific or non-native. 
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The structural and biochemical data also explain the lower affinity of metavinculin tail 
for PIP2 (66). Metavinculin has a threonine at position 978, which replaces R910 in Vt. The 
loss of one of the key residues for binding of PIP2 at the basic collar explains why 
metavinculin still binds PIP2, though weaker than Vt. 
The data presented here also support our recent structural model of the Vt-F-actin 
interaction, which highlights the role of helices 4 and 5, not helix 3. Further, actin co-
sedimentation assays reveal that mutation of the basic collar and basic ladder do not 
significantly affect actin binding. However, mutations at the basic collar do disrupt the 
ability of Vt to crosslink actin filaments into bundles (Figures 2.3, 2.4, 2.5). Even the use 
of conservative mutations to glutamine did not preserve Vt’s crosslinking activity. The 
failure of Vt LD-CT to crosslink F-actin further highlights the importance of the C-terminus 
in F-actin bundling (6, 115). The weaker crosslinking activity of Vt BC-2A and the nearly 
absent crosslinking activity Vt BC-4A suggest that residues R910, K915, K924, and R925 are 
integral in forming the Vt dimer. The failure of Vt BC-4Q to improve crosslinking activity 
over Vt BC-4A indicates that the positive nature of the helix 1-helix 2 loop is likely required 
for Vt to dimerize and crosslink actin filaments. It also provides new data to help develop a 
model for the actin-induced Vt dimer. 
These data provide new insights with which to develop better structural models for the 
vinculin:PIP2 interaction and, ultimately, better tools to study the biological function of this 
interaction. There remain further challenges to an accurate structural model, including 
understanding the conformational changes that take place when Vt binds to PIP2 (10) and 
the formation of higher order oligomers at membranes (10, 43, 66, 102). The Vt:PIP2 
structure by Chinthalapudi et al. identifies an oligomeric species that coordinates PIP2, but 
this model is unclear regarding how vinculin inserts into the membrane (40). Similarly, it 
does not show any significant conformation change in Vt upon binding this short-chain PIP2. 
While we favor our experimentally-derived computational model (Figure 2.2), additional 
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structural information derived from crystallography, NMR, or even cryo-electron 
microscopy of vinculin associated with PIP2 in lipid bilayers will aid in further 
understanding vinculin’s insertion into the membrane. Of the mutants described here, Vt 
BL-3A and Vt BL-4A are likely the best mutants to use in cells to study the biological role of 
the vinculin:PIP2 interaction. They exhibit a strong PIP2-binding defect, but, unlike the basic 
collar mutants, retain the ability to crosslink actin filaments. Cellular studies with these 
vinculin variants will be conducted to study the effects of the vinculin:PIP2 interaction of 
vinculin activation, vinculin localization, FA development, and force transduction. 
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Tm (C°) 
WT 76.8 ± 0.1 
BC-4A 66.5 ± 0.1 
BC-4Q 73.8 ± 0.1 
BL-4A 79.0 ± 0.2 
 
Table 2.1. Denaturation midpoints of Vt variants as assessed by CD thermal melts. 
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Figure 2.1. The basic collar and basic ladder of Vt. 
Shown on Vt (PDB file 1ST6) are the basic collar (A) and basic ladder (B) residues. The 
basic collar is comprised of K881, R910, K911, K915, K924, R925, R1057, R1060, and K1061, 
which are found in the N-terminal strap, helix 1, the helix 1-helix 2 loop, helix 2, and the C-
terminal hairpin. The basic ladder is comprised of K944, R945, K952, K956, R963, K966, 
K970, K975, and R976, which are found in helixes 3 and 4. Various studies have claimed that 
the basic ladder (3), the basic collar (2, 99, 101), or both (40-42) are responsible for PIP2-
binding by vinculin.  
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Figure 2.2. Modeling of the PIP2:Vt interaction. 
The results of MedusaDock (105, 106) (A), DMD (B), and GROMACS (C) simulations 
are shown. The MedusaDock simulations, using the PIP2 headgroup, identified residues 
R910, K915, K924, and R925 as residues that mediate PIP2 binding. These results were 
followed by DMD simulations with the full PIP2 molecule (B). The average number of heavy 
atom contacts with PIP2 is reported for each Vt residue in the three simulations. R910, K915, 
K924, and R925 are identified with vertical dashed lines. The basic collar shows the highest  
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amount of contact. The final pose of the GROMACS molecular dynamics simulation (C) 
shows PIP2 (green) still bound to the basic collar and residues K944 and R945 inserting into 
the lipid bilayer.  
27 
 
Figure 2.3. Actin-binding and crosslinking activity of Vt LD-CT (R1060Q/K1061Q). 
Shown are the results from actin co-sedimentation assays evaluating the ability of Vt 
LD-CT to bind (A) and crosslink (B) F-actin. Vt LD-CT binds to F-actin well, but is 
significantly impaired in its ability to crosslink F-actin.  
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Figure 2.4. Mutations at the basic collar disrupt binding to PIP2 and actin crosslinking 
functions. 
Shown are results from PIP2 co-sedimentation (A) and actin co-sedimentation (B, C) 
assays. Vt BC-2A and Vt BC-4A exhibit decreased binding to PIP2-containing liposomes (A). 
Vt BC-4A has a more severe PIP2-binding defect than Vt BC-2A, yet both retain F-actin 
binding function (B). Vt BC-2A and Vt BC-4A are impaired F-actin bundling (C), with Vt BC-
4A having the largest defect.   
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Figure 2.5. Mutation of basic collar residues to glutamine does not rescue F-actin 
crosslinking activity. 
Shown are the results of actin co-sedimentation assays measuring the ability of Vt BC-
4Q to bind (A) and bundle (B) F-actin. Vt BC-4Q contains more conservative mutations 
(basic to polar) than Vt BC-4A. Vt BC-4Q binds F-actin with a similar affinity to Vt WT. 
However, it, like Vt BC-4A, has a significant deficiency in actin crosslinking activity (C).  
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Figure 2.6. Mutations to the basic ladder disrupt PIP2 binding, but do not significantly 
impair F-actin binding or crosslinking. 
Shown are results from PIP2 co-sedimentation (A) and actin co-sedimentation (B, C) 
assays. Vt BL-2A, Vt BL-3A, and Vt BL-4A exhibit decreased binding to PIP2-containing 
liposomes (A), but retain F-actin binding (B) and crosslinking activity (C) in comparison to 
Vt WT. As with the basic collar mutations, mutating four residues in the basic ladder results 
in a stronger PIP2-binding defect.  
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Figure 2.7. CD characterization of basic collar and basic ladder mutants. 
Far-UV (A) and near-UV (B) spectra of Vt WT and Vt mutants. All constructs exhibit 
the characteristic signature of an α-helical protein (A). The near-UV spectra for Vt BL-4A 
suggests the packing interaction between W912 and W1058 has been altered, but not 
abolished, as characteristic peaks are present at 283 and 290 nm. The normalized thermal 
denaturation profiles for the Vt proteins (C) were adjusted by subtracting the buffer 
contributions and fit with a sigmoidal curve (D, Table 2.1). Mutations to the basic collar 
destabilize Vt, as evidenced by the decreased melting temperatures, though Vt BC-4Q, the 
more conservative variant, is more stable than Vt BC-4A. 
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Figure 2.8. Comparative lipid co-sedimentation assays for Vt BC-4Q and Vt BL-4A. 
Lipid-cosedimentation assays with PIP2-containing (A) or PS-containing liposomes. 
Both Vt BC-4Q and Vt BL-4A exhibit a PIP2-binding defect relative to Vt WT, as expected 
(A). Both variants also are defective in associating with PS-containing liposomes (B), though 
Vt BL-4A fares worse than Vt BC-4Q. In liposomes with 60% PS, only 2% of Vt BL-4A binds 
the liposomes, while 15% of Vt BC-4Q does. 
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Chapter 3: Structural, Biochemical, and Functional Characterization 
of the Actin-Binding Site on Vinculin Tail1 
Introduction  
Focal adhesions (FAs) and adherens junctions (AJs) are essential structures in 
eukaryotic cells that link cells to their environment: the extracellular matrix (ECM) and 
other cells, respectively. These structures serve both structural and signaling purposes, both 
of which are mediated through interactions with the actin cytoskeleton. Proper signaling 
between these adhesions and the actin cytoskeleton is essential for cell migration, cell 
survival, and the biological generation of force as reviewed by Gardel et al. (116). To ensure 
efficient signaling, a large number of proteins present at FAs and AJs can bind to and/or 
remodel the actin cytoskeleton.  
Vinculin is one such protein, though defining its interaction with actin has remained a 
difficult and somewhat contentious endeavor for scientists. The ability of vinculin bind F-
actin was debated for years after vinculin’s discovery until it was determined that the Vh:Vt 
interaction masks actin binding and must be disrupted for vinculin to bind actin (117). 
Subsequently, it has been shown that vinculin can cap actin filaments at the barbed end 
(inhibiting polymerization) (118), nucleate actin polymerization in low ionic strength buffer 
(119), and crosslink with other vinculin molecules to bundle F-actin filaments (120). While 
                                                        
1A significant portion of this chapter previously appeared in an article in Structure. The original 
citation is as follows:  
Thompson, P. M., Tolbert, C. E., Shen, K., Kota, P., Palmer, S. M., Plevock, K. M., Orlova, A., Galkin, 
V. E., Burridge, K., Egelman, E. H., Dokholyan, N. V., Superfine, R., and Campbell, S. L. (2014) 
“Identification of an actin binding surface on vinculin that mediates mechanical cell and focal 
adhesion properties,” Structure 22, 697-706. 
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these interactions have been studied biochemically, the lack of structural models for the 
interactions has hindered our understanding of their roles in a cellular context. 
Within the past eight years, a number of studies have been published attempting to 
describe, at greater resolution and with techniques other than random mutagenesis and 
deletions, the interaction of Vt with F-actin. The first such study was published by Janssen et 
al. and used mutageneis data from Cohen et al. (28) and negative-stain electron microscopy 
(EM) to propose two patches on Vt that bind two longitudinally adjacent F-actin protomers 
within the filment (121). These two patches, termed the “upper” and “lower” sites, were 
evaluated by Golji and Mofrad with molecular dynamics simulations (122). They identified 
interactions between Vt helix 4 not identified by Janssen et al., slightly shifting the perceived 
upper site. Additionally, they simulated Vt binding to the barbed end of the actin filament. 
Not long after, Thompson et al. used negative stain EM and new mutagenesis data to further 
support the role of helix 4, specifically its hydrophobic patch, in binding to F-actin (103). 
Their mutagenesis data provided two new vinculin mutants with the most significant actin-
binding defects reported (I997A and V1001A). Another point mutant, R1049E, was 
identified as being a weak actin binder, especially in low ionic strength solutions (123). This 
mutant disrupts binding at the lower site. These mutants, when used in cells, show that 
vinculin binding to actin is required for cell reinforcement, cell-spreading (103), cell 
migration, and generation of traction forces (123). Vinculin does this by binding to F-actin, 
slowing its retrograde flow, and altering the size, density, and growth rate of focal adhesions 
(124).  
No published structural model, however, perfectly accounts for all the data present. A 
significant part of this is that Vt undergoes a conformational change when it binds F-actin, a 
change that is not well-understood (120). The conformational changes are not large enough 
to see with negative stain EM due to the resolution limitations. Recent unpublished work out 
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of the Campbell and Alushin labs is beginning to identify the conformational changes using 
cryo-EM. Some of that work, as well as work published previously (103), is described below. 
Materials and Methods 
Protein expression and purification 
The plasmids for expression of vinculin and Vt were generated by the Liddington lab 
(2, 10) . The gene for full-length chicken vinculin (residues 1-1066) was placed in a pET15b 
vector. The gene for chicken Vt (residues 879-1066) was also placed into a pET15b vector for 
protein expression. All mutagenesis was performed using QuikChange site-directed 
mutagenesis (Stratagene, La Jolla, CA, USA) and the DNA sequence was verified by 
sequencing (Genewiz, RTP, NC, USA). 
To express either protein, chemically competent BL21 DE3 E. coli with the Rosetta2 
plasmid (EMD Millipore, Billerica, MA, USA) were transformed with the vector and plated 
on lysogeny broth (LB) plates containing ampicillin and chloramphenicol. A single colony 
was selected and grown overnight. The overnight growth was used to inoculate flasks with 1 
L LB. Cells were grown at 37C until OD reached 0.6. For full-length vinculin, expression 
was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and expression 
proceeded for three hours. For Vt, expression was induced with 250 μM IPTG and the 
incubator temperature was cut to 16-18 C, and cells were harvested after 16-20 hours. To 
harvest, cells were pelleted via centrifugation and then resuspended in lysis buffer (20 mM 
Tris, 150 mM NaCl, 5 mM imidazole, and 2 mM β-mercaptoethanol (BME)). Cells were lysed 
either with sonication or homogenization and the lysate was subsequently clarified by 
centrifugation at 25,000 × g for 45 minutes. Both full-length vinculin and Vt were purified 
using Ni-NTA beads (Qiagen, Germantown, MD, USA). The lysate was applied to the beads, 
which were subsequently washed with lysis buffer. For full-length vinculin, the beads were 
then washed with lysis buffer with 50 mM imidazole, while with Vt, the beads were washed 
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with lysis buffer with 60 mM imidazole. The protein was eluted with lysis buffer with 500 
mM imidazole.  
After purification by nickel column, proteins were dialyzed into thrombin cleavage 
buffer (20 mM Tris pH 7.5, 500 mM NaCl, 2 mM CaCl2, and 5 mM BME) and their histidine 
tags cleaved by addition of thrombin (Sigma-Aldrich, St. Louis, MO, USA). Proteins were 
then further purified by ion exchange chromatography (Q-column for vinculin, S-column for 
Vt) and size exclusion chromatography (S-200 superdex for both vinculin and Vt). 
IpaA peptide (Ac-NNIYKAAKDVTTSLSKVLKNIN-NH2) was provided by both the 
UNC Hight-Throughput Synthesis and Array Facility (Chapel Hill, NC, USA) and LifeTein 
(Hillsborough, NJ, USA). The lyophilized peptide was resuspended in actin co-
sedimentation buffer (10 mM Tris pH 7.5, 100 mM KCl, 2.5 mM MgCl2, and 2 mM 
dithiothreitol (DTT)) and centrifuged to remove aggregates and insoluble contaminants. 
Peptide concentration was determined by absorbance at 280 nm using an extinction 
coefficient of 1200 M-1 cm-1. 
Actin co-sedimentation 
Actin co-sedimentation assays were performed as previously described (6, 103). G-
actin was polymerized by addition of 2X and 1X actin co-sedimentation buffer so that the 
final concentration of actin is 45.6 μM and the buffer is at 1X. Polymerization was carried 
out for 30 minutes. Ten μL of 100 μM Vt or vinculin was then mixed with enough actin and 
buffer to give the reported actin concentration in a total volume of 100 μL. When using the 
IpaA peptide, 10 μL of a 1 mM stock was added to the reaction for a final peptide 
concentration of 100 μM. The volume for these reactions was also 100 μL. 
 The actin and vinculin or Vt were incubated together at room temperature for 1 hour. 
The samples were then spun for 30 minutes at 150,000 × g. The supernatant was collected 
by pipetting and the pellet resuspended in an equal volume of actin co-sedimentation buffer. 
The supernatant and pellet fractions were run on a gel using SDS-PAGE, and band 
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intensities were compared using ImageJ (104). The percentage of protein pelleted was 
calculated by dividing the intensity of the pellet band by the sum of the intensities of the 
pellet and supernatant bands. 
Circular dichroism 
Circular dichroism (CD) spectra were collected on a Jasco J-815 CD Spectrometer 
(JASCO, Easton, MD, USA). CD data were collected in 10 mM potassium phosphate, pH 5.5 
or pH 7.5, 50 mM Na2SO4, and 1 mM DTT at 25°C unless otherwise specified. For near-
ultraviolet (UV) measurements, protein was concentrated to 450 μM, while far-UV 
measurements were collected on protein at 5 μM. 
NMR spectroscopy 
To make uniformly 15N-enriched Vt for NMR, expression was done in M9 media with 
15NH4Cl as the sole nitrogen source. 15N-Vt was purified in the same manner as Vt from LB, 
exchanged into NMR buffer (10 mM potassium phosphate, pH 5.5, 50 mM NaCl, 0.1% NaN3, 
2 mM DTT, and 10% D2O), and concentrated to 50 μM. Two-dimensional heteronuclear 
single quantum coherence (HSQC) spectra were collected on a Varian INOVA 700 MHz 
spectrometer at 37°C. Spectra were processed with NMRPipe (125) and analyzed with 
NMRViewJ (126). 
Generation of negative stain EM images, manual fit model, and discrete molecular 
dynamics (DMD) model 
Collection of the EM images and generation of both structural models have been 
described by Thompson et al. (103). 
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Cell culture, cell-spreading assays, and microscopy 
Maintenance of vinculin-null mouse embryonic fibroblasts (Vin -/- MEFs), real-time 
cell analyzer (RTCA) assays, and microscopy were performed as previously reported (103, 
115). 
Results 
Mutation of the hydrophobic patch on Vt disrupts binding to F-actin 
For eight years after the publication of the first structural model for the interaction of 
Vt with F-actin (121), there were no specific mutations identified in vinculin that disrupted 
the interaction. This hampered the ability of cell biologists to tease out the role of vinculin’s 
interaction with F-actin without disrupting other interactions mediated by vinculin’s tail 
domain. The best mutation identified for disrupting actin binding, at that point, was a triple 
mutant, D959A/E960A/R963A, that disrupted binding to actin by 20% relative to wild type 
Vt (28).  
A former student in the Campbell lab, Sean Palmer, was trying to make mutations in 
Vt to disrupt its propensity to self-associate (Chapter 4) (127). This self-association is 
extremely weak (~330 μM) and is mediated through a hydrophobic patch on Vt that resides 
on helices 4 and 5 (10, 127). Surprisingly, mutations at this interface disrupted binding to F-
actin, even though these mutations were not near the actin-binding surfaces identified in the 
Janssen model. Specifically, Vt variants I997A and V1001A both significantly disrupted 
binding to F-actin (Figure 3.1) (103, 124), though I997A disrupts binding more. As 
expected, these mutations also impair Vt’s ability to bundle actin filaments (Figure 3.1). 
Mutations to L928 and I948, residues in the upper site defined by Janssen et al., fail to 
significantly disrupt F-actin binding (Figure 3.1).  
While Vt separates from the vinculin head domain upon vinculin activation, it was 
important to test the efficacy of these mutations in the context of the full-length vinculin 
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protein. Without the addition of IpaA peptide, neither wild type vinculin nor the actin-
binding deficient variants I997A and V1001A were able to bind, F-actin (Figure 3.1). This 
was expected, as vinculin must be activated by the presence of a head ligand to bind F-actin 
(117). The addition of an activating IpaA peptide, however, rescued actin binding in vinculin 
(103, 124). In I997A and V1001A vinculin, the addition of the IpaA peptide only partially 
rescued binding to F-actin (103, 124), showing that the actin-binding mutations have a 
similar effect in the context of the full-length protein. 
To test the structural integrity of these Vt variants, CD spectra were collected from 185 
nm to 350 nm. The far-UV spectra report on secondary structure, while the near-UV spectra 
report on packing of W912 and W1058. These spectra were collected at both pH 5.5 and pH 
7.5, as the charge on the sidechain of H906 has been reported to have a small effect on Vt 
structure (127, 128). The CD spectra show a small change in the helicity of Vt I997A at pH 
7.5, though the change is quite modest, suggesting that these mutations do not significantly 
impact the structure of Vt (Figure 3.2) (103). To further test the structural integrity, 1H-15N 
HSQC NMR spectra were collected. For both Vt I997A and V1001A, only a few residues show 
changes in their chemical shift values, and these residues are near to the sites of mutation, 
suggesting that any change in Vt structure caused by these mutations is small and localized 
(Figure 3.3) (103). The NMR and CD data suggest that both I997A and V1001A mutations 
do not significantly affect Vt structure and that the actin-binding defect of these Vt variants 
are due to disruption of the actin-binding site.  
Development of a new structural model for the interaction of Vt with F-actin 
Using the information from these mutations, new EM images of Vt-decorated F-actin, 
and computational modeling, two possible structural models for the interaction of F-actin 
with Vt were posited, a manual fit model and a discrete molecular dynamics (DMD) model 
(Figure 3.4) (103). These models fit both the EM data and the new mutation results. 
Additionally, they support the role of the previously identified lower site in binding, but 
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reassign the upper site to helix 4, not helix 2. These models place the hydrophobic patch on 
helix 4 of Vt in a hydrophobic groove in the actin filament (103). This groove is a canonical 
binding site for actin-binding proteins (129).  
While both the manual fit and DMD models place helix 4 in the hydrophobic groove in 
the actin filament, the orientation of Vt is quite different. In the manual fit model, the C-
terminal end of helix 4 faces the barbed end of the actin filament, while in the DMD model, 
the C-terminal end of helix 4 faces the pointed end (Figure 3.4). In this manner, the DMD 
model has Vt rotated 180° relative to the manual fit model. Because of the resolution 
limitations from the negative stain EM images, both models fit well into the three-
dimensional reconstruction and explain the effective disruption of actin binding by the 
I997A and V1001A mutations. 
Two additional mutations, T993A and E1015A, were made to further test these models. 
In both models, T993 faces F-actin, though only in the DMD model does the sidechain of 
E1015 face F-actin (Figure 3.4). Both of these mutations decrease actin binding, though the 
effects are weaker than the I997A and V1001A mutations (Figure 3.1). These additional 
data support choosing the DMD model over the manual fit model, though they are not 
sufficient to eliminate consideration of the manual fit model. 
Disruption of F-actin binding increases F-actin flow at focal adhesions, altering adhesion 
size and function 
With the development of point mutations in vinculin with specific defects in F-actin 
binding, the tools were in place to evaluate the roles of actin-binding by vinculin in cell and 
FA biology without disrupting many of vinculin’s other functions. Using vinculin-null mouse 
embryonic fibroblasts (Vin-/- MEFs) expressing vinculin I997A, Thievessen et al. showed 
that vinculin acts as a clutch to mechanically link F-actin flow to FAs. This regulation of actin 
flow is coupled to FA growth, suggesting that, by regulating actin flow, vinculin helps 
regulate the growth of FAs. 
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 To further examine the role of actin-binding, Thompson et al. expressed vinculin 
I997A and vinculin V1001A in Vin-/- MEFs. MEFs expressing vinculin I997A or vinculin 
V1001A had slightly fewer, but larger FAs, similar to what Thievessen et al. observed 
(Figure 3.5) (103, 124). To test the ability of these cells to respond appropriately to external 
forces, three dimensional force microscopy (130) was used. MEFs expressing the various 
vinculin constructs were plated and then magnetic beads coated in fibronectin (FN) were 
added. After time passed to allow for FAs to develop between the MEFs and the beads, 
successive pulses of magnetic force were applied. MEFs expressing wild type vinculin 
underwent a strengthening of their focal adhesions, reinforcement, which decreased the 
movement of beads upon successive pulses. However, MEFs expressing vinculin I997A or 
vinculin V1001A failed to reinforce (Figure 3.6) (103). 
 Vinculin has also been implicated as having a role in cell spreading, though the role 
of actin-binding in this function is unknown (4). Vin-/- MEFs and Vin-/- MEFs expressing 
vinculin, vinculin I997A, and vinculin V1001A were allowed to spread on FN and monitored 
with the xCELLigence real-time cell analyzer system (131). Vin-/- MEFs exhibited a spreading 
defect, as evident by the lower cell index readout, which was only partially rescued by 
vinculin I997A or vinculin V1001A (Figure 3.7) (103). This suggests that, while actin-
binding by vinculin plays a role in cell-spreading, it is not the only vinculin function involved 
in regulation of cell spreading. 
Cryo-EM modeling reveals details of Vt conformational change 
Vt undergoes a conformational change when it binds to F-actin, though the structural 
details of the conformational change are relatively unknown (10, 120). Bakolitsa et al. 
showed that actin-binding by Vt leads to an increase in susceptibility to proteolytic cleavage 
at A901 and S913, residues that start and end helix 1. Because of the lack of structural 
information, interpreting structural and biochemical data regarding the Vt:F-actin 
interaction has been difficult.  
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Collaboration with the Alushin Lab at the National Heart, Lung, and Blood Institute 
was initiated to address some of these concerns. Using cryo-EM and Vt ΔC5, a Vt variant 
defective in actin bundling (6), an 8.5 Å structural model for Vt bound to F-actin was 
developed (Figure 3.8) (132). This model shows two key conformational changes that take 
place upon actin binding: the straightening of helix 4, which is kinked by the presence of 
P989, and the displacement of helix 1 (Figure 3.9). Whether helix 1 unfolds or remains a 
helix and whether it has any interactions with F-actin is unclear, though there is some 
evidence that it may bind to the barbed-end actin protomer (unpublished). However, it is 
clear that binding to F-actin converts Vt structure from a five-helix bundle to a four-helix 
bundle. 
While the 8.5 Å resolution of the cryo-EM model limits the detail with which 
conformational changes in Vt can be described, it does provide insight to the mode of actin 
binding. In comparing the cryo-EM model to the published models (103, 121, 122), it is clear 
that, while none of the previous models could predict the Vt conformational changes, the 
DMD model published by Thompson et al. comes the closest to predicting the actin-binding 
surface on Vt (Figure 3.8) (103). Though the resolution limitation precludes the 
identification of specific contacts made by sidechains, those closest to F-actin are more likely 
to interact. Thus, to further test the validity of the cryo-EM model, two Vt residues that had 
not been mutated, R987 and M1022, previously were mutated to alanine. Actin co-
sedimentation assays show that these mutants disrupt binding to F-actin (Figure 3.10). 
These mutations are not as severe in their binding defect as I997A or V1001A, but R987 and 
M1022 are located further from the center of the upper actin-binding site on Vt. 
 Discussion 
For a protein like vinculin with many different functions, determining the biological 
role of any one particular function presents a significant challenge, as special care must be 
taken to target only the desired function. The lack of a good structural mode l for vinculin 
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bound to F-actin has long hampered a better understanding of the biological role of this 
interaction. This has been further complicated by the conformational change that vinculin 
undergoes upon binding to F-actin and by the intrinsic difficulties F-actin poses to structural 
biologists.  
Using some fortuitous mutagenesis results, a combination of EM, modeling, and 
biochemical techniques, the highest-resolution model for the interaction of vinculin with F-
actin has been developed. This model confirms that the upper F-actin binding site on Vt is 
localized to the hydrophobic patch on helices 4 and 5 (103). Additionally, the Vt helix bundle 
loses helix 1, becoming a four-helix bundle upon binding to F-actin, explaining the limited 
proteolysis data suggesting an increase in flexibility around helix 1 (10). The predictive 
power of this structural model in disrupting actin binding further supports its validity. 
The development of these structural models has allowed for rational use of specific 
point mutations in cells to determine the biological role of actin binding by vinculin. Actin-
binding by vinculin regulates FA growth and maturation, affecting both cell spreading and 
mechanotransduction in mouse fibroblasts. Further experiments using vinculin mutants 
selectively deficient in F-actin binding showed that, by binding to actin, vinculin serves as a 
mechanical clutch at FAs to regulate retrograde actin flow, which is an important factor 
regulating FA development (124). 
With the tools now in place, future studies should be able to determine the role of actin 
binding by vinculin at adherens junctions and in cellular migration. Additionally, the role of 
actin binding by metavinculin can now also be evaluated using the tools reported here. As 
vinculin’s role in cancer becomes more defined, the role of actin binding by vinculin in both 
tumor growth and in metastasis will be of interest. If actin binding by vinculin is important 
for cancer progression, perhaps the Vt conformational change can be targeted as a 
therapeutic.  
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Figure 3.1. Mutations at and near I997 and V1001 disrupt F-actin binding. 
Shown are actin results from actin co-sedimentation assays. Panel A is an actin 
binding co-sedimentation, showing that I997 and V1001 are important residues for Vt 
binding to F-actin. I948 and L928, residues at the binding surface for a different model 
(121), are not involved in binding to F-actin. Panel B shows that actin-binding defects result 
in actin-bundling defects. Panel C shows that the defects are not a consequence of working 
with just Vt, but that full-length vinculin with these mutations has an actin-binding defect. 
45 
 
Figure 3.2. CD spectra of Vt variants. 
The CD spectra for Vt, Vt I997A, and Vt V1001A are shown for far-UV wavelengths (A, 
C) and near-UV wavelengths (B, D) at pH 5.5 (A, B) and 7.5 (C, D). The spectra are very 
similar, except for Vt I997A. The near-UV spectra for Vt I997A appear to be shifted, even 
though they retain the peaks at 283 and 290 nm associated with the packing of W912 and 
W1058 in Vt.  
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Figure 3.3. 1H-15N HSQC spectra of Vt, Vt I997A, and Vt V1001A. 
Shown are NMR spectral overlays of Vt I997A (A) and Vt V1001A (B) over Vt. The 
majority of peaks do not shift, and those that do are mostly near the site of mutation. The 
mutated residues are labeled and shown as sticks on Vt (PDB file 1ST6). Residues whose 
peaks shift are colored red, and those that broaden are colored orange.  
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Figure 3.4. The manual fit and DMD models for the binding of Vt to F-actin. 
Shown are the manual fit (above) and DMD (below) models for Vt bound to F-actin. F-
actin is in green, with the pointed end protomer in dark green and the barbed end protomer 
is in light green.Vt is in a blue shade, with helix 4 in purple (manual fit) or pink (DMD). 
Residues T993, I997, V1001, and E1015 are shown as sticks. These residues, when mutated 
to alanine, weaken the binding affinity of Vt for F-actin. The two models both have helix 4 
facing the actin filament; however, the manual fit model has the C-terminus closer to the 
pointed end and the DMD model has the C-terminus closer to the barbed end. 
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Figure 3.5. Loss of actin-binding function in vinculin results in fewer, but larger, FAs. 
Panel A shows representative images of Vin -/- MEFs expressing wild type (WT), 
V1001A, or I997A GFP-tagged vinculin. The vinculin mutants localize normally to focal 
adhesions. The scale bar is 25 μm. Panels B, C, and D are box plots that show the average 
size of FAs, average number of FAs, and the cell area, respectively, for Vin -/- MEFs 
expressing these vinculin constructs. Cells expressing vinculin V1001A or vinculin I997A 
have significantly fewer, but larger FAs. Cells expressing vinculin I997A are significantly 
smaller. This may be due to a mild PIP2-binding defect or the increased severerity of the 
actin-binding defect relative to vinculin V1001A. * represents p<0.05. Figure adapted with 
permission from Thompson et al. (103).  
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Figure 3.6. Actin-binding by vinculin is required for reinforcement at FAs. 
Vin -/- MEFs expressing wild type vinculin (WT), vinculin V1001A, or vinculin I997A 
were incubated with magnetic beads coated in fibronectin. Pulses of force were then applied 
to the beads and the bead displacement measured. The normal cellular response is a 
stiffening, resulting in a smaller displacement of the bead upon the second pulse. MEFs 
expressing vinculin constructs with an actin-binding defect are not able to reinforce. The 
greater defect for MEFs expressing vinculin I997A could be from the stronger actin-binding 
defect or the slight PIP2-binding defect. * represents p<0.05 and *** represents p<0.001. 
Figure adapted with permission from Thompson et al. (103). 
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Figure 3.7. Cell spreading of Vin -/- MEFs expressing various vinculin constructs. 
Panel A is the raw data from the RTCA experiment. Data were collected for Vin -/- 
MEFs expressing wild type vinculin (WT, red), vinculin V1001A (blue), vinculin I997A 
(green), or no vinculin (magenta). Vinculin mutants with actin-binding defects only partially 
rescue the poor spreading phenotype in the vinculin null cells. Panel B shows the relative cell 
index at the 2 hour timepoint. * represents p<0.05. Figure adapted with permission from 
Thompson et al. (103).  
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Figure 3.8. The cryo-EM model of Vt bound to F-actin. 
Shown is the model of Vt bound to F-actin derived from cryo-EM data (A). Vt is in 
orange and F-actin in cyan. Panel B compares the DMD model with the cryo-EM model. The 
color scheme is maintained from Figure 3.4. The cryo-EM model is similar in that helices 4 
and 5 are involved in actin binding. Discrepancies between the two models are, in large part, 
due to the conformational changes in Vt that are observed in the cryo-EM model.  
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Figure 3.9. The Vt helix bundle changes conformation upon binding F-actin. 
Shown in Panel A is a comparison of the structure of unbound Vt (gray, PDB file 1ST6) 
with Vt from the cryo-EM model of Vt bound to F-actin (blue and pink, Figure 3.8). The 
color scheme is maintained from Figure 3.8. Panel B shows how helix 4 straightens 
considerably upon binding F-actin. Lines have been draws along helix 4 to highlight this 
change, with long dashes for unbound Vt and small dashes for the cryo-EM model of bound 
Vt. To help compensate for this straightening, helices 3 and 5 shift slightly, with helix 3 
moving out from the bundle at its C-terminus and helix 5 moving back to the bundle at its C-
terminus. Note that helix 1 is not present in the cryo-EM model, suggesting it leaves the helix 
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bundle. Panel B removes helix 1 from the unbound Vt to show how helices 2 and 5 shift 
towards each other. This shift suggests that helix 1 is excluded and blocked from accessing 
the hydrophobic core of the bundle.   
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Figure 3.10. Two model-predicted mutants disrupt F-actin binding. 
Panel A shows the cryo-EM model. The color scheme is the same from Figure 3.8. 
Helix 4 is colored in pink, and the labeled residues have their sidechains shown with sticks. 
Q983, R987, and M1022 are in orange, and were identified as Vt residues that contact F-
actin. Panel B shows the results of actin co-sedimentation assays done to assess the 
contribution of these residues. Mutation to alanine of R987 and M1022 result in a slight 
actin-binding defect. Mutation of Q983 has no significant effect on actin binding. 
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Chapter 4: Characterization of Vt Q1018K, a Vt variant with a 
Decreased Propensity for Self-Association at High Concentrations 
Introduction  
Vinculin and Vt have been studied extensively by crystallography, providing a number 
of static crystal structures of Vt (2, 10, 39, 133). These structures have shown that Vt has the 
same general structure, a five-helix bundle, independent of binding to the vinculin head 
domain. Additionally, the binding sites for F-actin and PIP2 are localized to Vt (86, 134), 
suggesting that study of the isolated Vt reasonably mimics native structure and interactions. 
It has become apparent that, on its own or in the presence of ligands, Vt has a propensity to 
oligomerize. Upon binding of Vt to F-actin (120, 121) or PIP2 (10, 66, 102) and subsequent 
addition of a crosslinking agent, dimers and higher-order oligomers are observed. The F-
actin-induced dimer is responsible for F-actin crosslinking by Vt (120), which is essential for 
proper focal adhesion development and force transduction, though the structure of this 
oligomer is unknown. The structural and functional natures of the PIP2-induced oligomers 
have not been well defined. Recently a crystal structure of Vt with a short-chain PIP2 
molecule has been solved (40), though the physiological relevance of this oligomer is 
somewhat questionable, as its formation in the presence of a lipid bilayer is unlikely. The 
oligomerization of Vt in the absence of ligands has also been reported, though at a much 
lower Kd than in the presence of ligands (127, 128).  
Not surprisingly, when the structure of Vt was first solved, it was solved as a dimer 
(10). The dimer in the crystallographic space group has the C-terminal arm of one Vt pack 
against the N-terminal strap and helix 1 of the second Vt (Figure 4.1) (10). In addition to 
this dimer, a second dimer is formed across the repeating units (Figure 4.1), which is the 
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dimer that forms when Vt is found at higher concentrations (> 50 µM) in solution (10, 127). 
This dimer is mediated by a hydrophobic patch on helices 4 and 5 (Figure 4.1). The Kd for 
this dimer is reported to be roughly 300 μM. Given the physiological concentrations of 
vinculin in vivo, this dimer is unlikely to be physiologically relevant and does not contribute 
significantly in most biochemical assays (127). However, nuclear magnetic resonance (NMR) 
experiments often require concentrations greater than 200 μM, at which roughly 43% or 
more of Vt would exist in this weak, self-associative dimer. As NMR is highly sensitive to the 
rotational correlation time of molecules in solution, with sensitivity and detection more 
difficult as the molecular size increases, dimerization of Vt limits NMR structural and 
dynamic analyses.  
NMR spectroscopy is a biophysical technique that uses the property of nuclear spin to 
obtain specific signals for each nucleus in a molecule. The frequency of the signals originates 
from the precession of the magnetic moment of the nuclear spin, which is dependent on the 
electrochemical environment of the nucleus. Additionally, the relaxation of the nuclear 
magnetic moment provides information on the motion of the nucleus. The transverse 
relaxation (R2) is quite sensitive to this, and also scales with the size of the molecule. A Vt 
dimer, at 43 kDa, has unfavorable relaxation properties, further making NMR an unsuitable 
technique for the study of Vt. To overcome these limitations, a Vt variant was designed to 
weaken the affinity of this dimer and allow for the study of Vt by NMR as well as other 
biophysical/structural approaches. 
Materials and Methods 
Protein expression and purification 
The plasmid for expression of Vt was generated by the Liddington lab (10) . The gene 
for chicken Vt (residues 879-1066) was placed into a pET15b vector for protein expression. 
All mutagenesis was performed using QuikChange site-directed mutagenesis (Stratagene, La 
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Jolla, CA, USA) and the DNA sequence was verified by sequencing (Genewiz, RTP, NC, 
USA). Additionally, the Vt gene was cloned into the pQLinkH vector using BamHI and NotI 
as the 5’ and 3’ restriction endonucleases, respectively. pQLinkH, like pET15b, codes for an 
N-terminal histidine tag to the protein. However, it codes for a TEV protease cleavage site 
instead of a thrombin cleavage site. 
To express Vt, chemically competent BL21 DE3 E. coli with the Rosetta2 plasmid 
(EMD Millipore, Billerica, MA, USA) were transformed with either vector and plated on LB 
plates containing ampicillin and chloramphenicol. A single colony was selected and grown 
overnight. The overnight growth was used to inoculate flasks with 1 L Luria Broth. Cells were 
grown at 37C until OD reached 0.6. Expression was induced with 250 μM IPTG, the 
incubator temperature was cut to 16-18 C, and cells were harvested after 16-20 hours. To 
harvest, cells were pelleted via centrifugation and then resuspended in lysis buffer (20 mM 
Tris, 150 mM NaCl, 5 mM imidazole, and 2 mM β-mercaptoethanol (BME)). Cells were lysed 
either with sonication or homogenization and the lysate was subsequently clarified by 
centrifugation at 25,000 × g for 45 minutes. The first purification step was over Ni-NTA 
beads (Qiagen, Germantown, MD, USA). The lysate was applied to the beads, which were 
subsequently washed with lysis buffer. The beads were then washed with lysis buffer with 60 
mM imidazole. The protein was eluted with lysis buffer containing 500 mM imidazole.  
After purification using nickel-agarose beads, vinculin protein expressed in the 
pET15b system was dialyzed into thrombin cleavage buffer (20 mM Tris pH 7.5, 500 mM 
NaCl, 2 mM CaCl2, and 5 mM BME) and the histidine tag cleaved by addition of thrombin 
(Sigma-Aldrich, St. Louis, MO, USA). Proteins were then further purified by ion exchange 
chromatography (S-column) and size exclusion chromatography (S-200 superdex). 
For expression using the pQLinkH vector, vinculin proteins were purified by nickel 
affinity chromatography and the N-terminal histidine tag was cleaved by the addition of TEV 
protease. The mixture was dialyzed overnight at room temperature into TEV cleavage buffer 
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(20 mM Tris pH 7.5, 50 mM NaCl, 5 mM BME). The protein mixture was then passed over 
Ni-NTA beads a second time to remove the histidine tag, TEV protease, and any 
contaminating proteins that bound to the Ni-NTA beads. After this step, ion exchange and 
size exclusion chromatography were used to further purify the protein sample. 
Analytical ultracentrifugation 
Sedimentation equilibrium data were collected as previously described (127). 
Experiments were run on a Beckman Optima XL-I analytical ultracentrifuge with a Ti50 8-
hole rotor and six-sectored centerpieces. Samples were dialyzed into analytical 
ultracentrifugation (AUC) buffer (10 mM potassium phosphate pH 7.5, 50 mM NaCl, 2 mM 
dithiothreitol) and concentrated. Samples were run first at 3000 rpm to obtain a flat line 
and to estimate the extinction coefficient at 305 nm. Absorbance was measured at 305 nm 
because the concentrations of Vt used were too large to get reliable readings at 280 nm. 
Samples were then spun at 19000 rpm for 20 hours, with measurements collected every two 
hours. Finally, samples were spun at 40000 rpm for eight hours with measurement collected 
at every two hours to determine the meniscus depletion and provide an offset for the 
absorbance of the buffer. 
Data were analyzed using WinNonlin V1.06 (D. Yphantis, University of Connecticut, 
Storrs, CT; M. Johnson, University of Virginia, Charlottesville, VA; J. Lary, National 
Analytical Ultracentrifugation Facility Center) as reported previously (127). 
Circular dichroism 
Circular dichroism (CD) spectra were collected on a Jasco J-815 CD Spectrometer 
(JASCO, Easton, MD, USA). CD data were collected in 10 mM potassium phosphate, pH 5.5 
or pH 7.5, 50 mM Na2SO4, and 1 mM DTT at 25°C unless otherwise specified. For near-
ultraviolet (UV) measurements, protein was concentrated to 450 μM, while far-UV 
measurements were collected on protein at 5 μM. 
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NMR spectroscopy 
To make uniformly 15N-enriched Vt for NMR studies, Vt was expressed in M9 media 
with 15NH4Cl as the sole nitrogen source. 15N-Vt was purified in the same manner as Vt from 
lysogeny broth (LB), exchanged into NMR buffer (10 mM potassium phosphate, pH 5.5, 50 
mM NaCl, 0.1% NaN3, 2 mM DTT, and 10% D2O), and concentrated to 30 μM. For uniformly 
15N- and 13C-enriched Vt, M9 media was used with 15NH4Cl (1 g/L) and 13C-D-glucose (2 g/L) 
as the nitrogen and carbon sources (Cambridge Isotope Laboratories, Tewksbury, MA, USA). 
Two-dimensional heteronuclear single quantum coherence (HSQC) spectra were collected 
on a Varian INOVA 600 MHz spectrometer at 37°C. HNCA and HNCO spectra for backbone 
assignments were collected on a Varian INOVA 700 MHz spectrometer at 37°C. The HNCO 
was collected using 16 transients, 32 real increments in the 15N dimesion, and 38 real 
increments in the 13C dimension. The HNCA was collected using 32 transients, 30 real 
increments in the 15N dimesion, and 52 real increments in the 13C dimension. Spectra were 
processed with NMRPipe (125) and analyzed with NMRViewJ (126).  
Size exclusion chromatography 
For evaluation of self-association, samples were run over Superdex 75 10/300 GL 
column run by an AktaFPLC (GE Healthcare Life Sciences, Pittsburgh, PA, USA). Sample 
volume was 500 μL at the reported concentration. AUC buffer was flowed over at a rate of 
0.5 mL/minute and absorbance at 280 nm was recorded to track protein elution. 
Actin co-sedimentation 
Actin co-sedimentation assays were performed as previously described (6, 103). G-
actin was polymerized by addition of 2X and 1X actin co-sedimentation buffer so that the 
final concentration of actin is 45.6 μM and the buffer is at 1X. Polymerization was carried 
out for 30 minutes. Ten μL of 100 μM Vt was mixed with enough actin and buffer to give the 
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reported actin concentration (0, 5, 10, 20, and 30 µM) in a total volume of 100 μL to give 
Vt:F-actin molar ratios of 1:0, 1:0.5, 1:1, 1:2, and 1:3.  
Actin and Vt were incubated together at room temperature for 1 hour. The samples 
were then spun for 30 minutes at 150,000 × g. The supernatant was collected by pipetting 
and the pellet resuspended in an equal volume of actin co-sedimentation buffer. The 
supernatant and pellet fractions were run on a gel using SDS-PAGE, and band intensities 
were compared using ImageJ (104). The percentage of protein pelleted was calculated by 
dividing the intensity of the pellet band by the sum of the intensities of the pellet and 
supernatant bands. Values were adjusted to fit the percentages published previously (6, 43) 
by fitting to a binding curve and scaling the respective Kd values. 
Results 
Mutation of Q1018 to lysine disrupts Vt self-association at high concentrations 
To study Vt by NMR requires the overcoming of certain technical challenges imposed 
by its propensity to self-associate. With the reported Kd of 300 μM, (127), one must choose 
to either run experiments at a low concentration or to study Vt as a dimer. Low 
concentrations necessitate prohibitively long NMR collection times for three-dimensional 
experiments or those designed to record relaxation properties. Studying the self-associating 
Vt dimer is not an attractive option, as it is a non-physiological oligomer with a molecular 
weight of 43.2 kDa, placing it near the upper size limit for structures amenable to NMR. 
Therefore, mutations at the self-associative interface (PDB file 1QKR) (10) were made to 
weaken this interaction and make Vt more amenable to NMR. Two such mutations, I997A 
and V1001A, disrupt sefl association, but exhibit poor binding to F-actin (103). A different 
mutation, Q1018K, was also made, with the intention of it not disrupting binding to F-actin. 
This mutation introduces two positive charges into the self-associative interface to decrease 
the affinity of the interaction with electrostatic repulsion. 
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To evaluate the self-association properties of Vt Q1018K, Vt and Vt Q1018K were 
sedimented using an analytical ultracentrifuge. Vt was centrifuged at concentrations of 470, 
450, 313, 300, 157, and 150 μM, while Vt Q1018K was centrifuged at 600, 400, and 200 μM. 
Data were fit to using the monomer/dimer self-association model, both with and individual 
fit for each concentration and a collective fit, with and without offset values determined by 
spinning at 40,000 rpm (Figures 4.2 and 4.3). The fits were not particularly good, as 
evidenced by the residuals and the reported errors. Additionally, the Kd for the fit of Vt is 
much larger than 300 μM (Table 4.1). These results suggest that, at the concentrations 
used, Vt may be forming trimers or other higher-order oligomers. However, the self-
association affinity for Vt Q1018K is slightly lower than that for Vt, suggesting that this 
mutation may weaken the association interface. 
To follow up on these results, both Vt and Vt Q1018K were run on a size exclusion 
column at various concentrations. Vt Q1018K eluted at the size of a Vt monomer at 200 μM, 
suggesting that the Kd for its self-association is greater than that reported for wild type Vt 
(Figure 4.4). An NMR titration was also collected with Vt Q1018K to evaluate its self-
associative properties. The 1H-15N chemical shifts for the backbone amide of T962 and S1016 
are good probes for formation of the dimer, as they shift as Vt concentration increases (127). 
Unlike Vt, there was no evidence of Vt Q1018K dimerization at 200 μM and only slight 
dimerization at 650 μM by these resonances (Figure 4.5). These experiments, in 
conjunction, show that the Kd for Vt Q1018K self-association is higher than Vt, indicating 
that the Vt Q1018K variant is amenable to detailed NMR studies. 
Vt Q1018K is structurally similar to wild type Vt 
Though Vt Q1018K shows reduced concentration-dependent self-association, for it to 
be a suitable substitute for wild type Vt in NMR experiments, it must be structurally similar 
to Vt. Circular dichroism (CD) of Vt and Vt Q1018K was used to assess secondary structure 
and tryptophan packing. At both far- and near-UV wavelengths, Vt Q1018K exhibited the 
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characteristic spectra of a well-folded Vt protein (Figure 4.6). The far-UV spectrum 
revealed the secondary structure of Vt Q1018K to be dominated by α-helical and the near-UV 
spectrum revealed the characteristic peaks at 283 and 290 nm indicative of the correct 
packing of the tryptophan 912 and tryptophan 1058 sidechains. These results suggest that 
mutation of glutamine 1018 to lysine does not significantly alter the structure of Vt. 
In addition to evaluating the structure of Vt Q1018K by CD, NMR was also used to 
examine any potential change in Vt structure. A 1H-15N two-dimensional (2D) HSQC reveals 
that there are a substantial number of peaks that shift relative to Vt (Figure 4.7). These 
resonances all shifted by greater than twice the average linewidth of the NH peaks. This was 
not surprising, as the backbone resonances were assigned under conditions at which the Vt 
dimer was the prevalent speicies (135). The NH backbone resonances that shift correspond 
to V985, E986, R987, T993, K996, I997, L998, S999, E1014, S1016, L1023, V1024, and 
I1046. The majority of these residues are located near the site of mutation, residue 1018, as 
expected. These results suggest that, while there may be some small, local changes to the 
structure of Vt upon mutation of glutamine 1018 to lysine, the protein retains its structure 
(Figure 4.7). This makes Vt Q1018K a valuable tool for studying Vt by NMR. 
Vt Q1018K has a slight actin-binding defect 
Because Vt I997A and Vt V1001A greatly impair binding to F-actin (103), these 
variants were not ideal for study by NMR, as the biochemical function of Vt was significantly 
disrupted. We tested Vt Q1018K for its actin-binding properties by actin co-sedimentation to 
ensure that it could still bind and crosslink F-actin. Vt Q1018K does exhibit a slight binding 
defect, as it binds to 30 µM F-actin at 87% of the level that Vt binds F-actin (Figure 4.8). 
This is congruent with the most recent Vt:F-actin structural model, as Q1018 is in helix 5, 
near the edge of the actin-binding interface. However, this change in binding is modest 
compared to mutations at the hydrophobic core of this upper site (Chapter 3). 
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NMR backbone assignment of Vt Q1018K 
The 1H-15N HSQC of Vt Q1018K exhibited shifts for at least 8.4% of the NH peaks, 
necessitating the assignment of Vt Q1018K backbone residues. Both three-dimensional 
HNCA and HNCO data were collected for 15N-13C labeled Vt Q1018K at a concentration of 
200 μM. This was done without perdeuteration, which was required for the assignment of 
Vt, and practically removes the potential for signal from the Vt self-associated dimer. 
Assignments were made for 81.52% of the non-proline 15N and 1H resonances, compared to 
84.24% of the non-proline 15N and 1H resonances for Vt (Figure 4.9) (135). The residues 
that were assigned for Vt but not for Q1018K are R903, I920, A922, A927, and L936, which 
are found in helix 1, helix2, or the helix 2-helix 3 loop.  
Discussion 
The ability of Vt to self-associate at high concentrations in a non-physiological manner 
limits the techniques and analyses available for studying Vt. The generation of Vt Q1018K, a 
Vt variant with a weaker affinity for the self-associative dimer in the absence of Vt ligands, 
provides a way to overcome many of these limitations. Though the AUC, size exclusion, and 
NMR data, individually, could not be used to quantify the Kd of the associative interaction 
for Vt Q1018K, these data taken together indicate that Vt Q1018K has a weaker Kd for self-
association. These data are further supported by the correlation time of Vt Q1018k, 11.86 
ns/rad (Chapter 5). This correlation time is indicative of a protein of roughly 20 kDa , 
slightly less than the calculated weight of monomeric Vt (136). 
Not surprisingly, mutations that weaken this self-associative interface also weaken F-
actin binding (103, 124), as the self-associative interface overlaps significantly with the 
upper actin binding site (103). Mutation of Q1018 to lysine avoids a large disruption of actin-
binding, as seen with I997A and V1001A, while still disrupting self-association, making it a 
suitable candidate for studying Vt at high concentrations without disrupting its biochemical  
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functions. Indeed, the development of this tool has allowed for the utilization of a wide range 
of NMR experiments to study Vt, some of which have been published previously (103) and as 
well as applications discussed in Chapter 5.  
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 K
d
 (mM) 95% confidence interval (mM) 
Vt 1.26 0.81-2.06 
Vt Q1018K 1.53 0.98-2.47 
 
Table 4.1 Kd values for Vt and Vt Q1018K self-association as determined by AUC. 
The Kd values and 95% confidence intervals for the fits of the AUC data for Vt and Vt 
Q1018K to a monomer/dimer model are reported. 
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Figure 4.1. The structure of the Vt homodimer. 
At high concentrations Vt self-associates to form a homodimer. This interaction is 
mediated primarily by the hydrophobic patch present on helices four and five. Isoleucine 
997 and valine 1001 are shown in yellow and orange, respectively, and are the residues at the 
core of this interface. Glutamine 1018 is shown in magenta. The sidechains of these residues 
are shown as sticks. 
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Figure 4.2. Sedimentation curves for Vt. 
Sedimentation curves for Vt at six different concentrations are displayed with a fit to a 
monomer/dimer model. Residuals are also shown. 
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Figure 4.3. Sedimentation curves for Vt Q1018K. 
Sedimentation curves for Vt Q1018K at three different concentrations are displayed 
with a fit to a monomer/dimer model. Residuals are also shown. 
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Figure 4.4. Size exclusion chromatography of Vt and Vt Q1018K. 
The elution profiles for Vt and Vt Q1018K from a 25-mL Superdex-75 column. Vt runs 
are shown in black and Vt Q1018K elution profiles are shown in red, with the respective 
concentrations listed in the legend. 
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Figure 4.5. HSQC titration of Vt Q1018K. 
Overlaid spectra of 1H-15N HSQCs collected at various Vt Q1018K concentrations. The 
colors of the peaks (black, blue, red) correspond to the concentration of Vt Q1018K in the 
sample (40, 200, and 650 μM, respectively). The second panel highlights T962 and S1016, 
which have shifted NH resonances when Vt is dimeric (127). There is very little shift for 
these resonances, suggesting minimal dimer formation.  
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Figure 4.6. CD of Vt and Vt Q1018K. 
Far- and near-UV CD spectra (A and B, respectively) of Vt and Vt Q1018K. Vt is in red, 
Vt Q1018K is in blue. Spectra are similar, suggesting that the structure of Vt Q1018K is very 
similar to Vt. 
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Figure 4.7. 1H-15N HSQC overlay of Vt and Vt Q1018K. 
The overlay of the 1H-15N HSQC spectra of Vt (black) and Vt Q1018K (red) are shown 
in A. The residues that exhibit a significant change in chemical shift values (difference 
greater than twice the linewidth) are mapped onto the Vt structure (PDB code 1ST6) in 
green. Residues in black do not have assignments for amide hydrogens or nitrogens in Vt. 
The Q1018 sidechain is shown in spheres. 
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Figure 4.8. Actin binding of Vt Q1018K. 
Actin co-sedimentation results with Q1018K. In A, a gel is shown with the pellet (P) 
and supernatant (S) fractions from a co-sedimentation assay. Vt Q1018K does bind to F-
actin. In B, the relative binding amounts of Vt Q1018K to Vt at 30 μM F-actin are shown with 
error bars reporting standard deviation. 
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Figure 4.9. Assignment of Vt Q1018K. 
NMR spectrum of Vt Q1018K showing backbone amide hydrogens and nitrogen 
assignments (A). Peaks with boxes have been assigned. The residues that were not assigned 
are shown on the Vt structure (B, PDB code 1ST6). Pink residues are assigned for Vt but not 
Vt Q1018K, and black residues are not assigned. The Q1018 sidechain is shown with spheres. 
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Chapter 5: Characterization of the Role of Vt Backbone Dynamics and 
Proline 989 in Vt Function 
Introduction  
Vinculin is a scaffolding protein that plays an important role in cell adhesion and 
migration (9). The ability of vinculin to act as a scaffold involves ligand-induced 
conformational changes that separate the head and tail domain (2, 10, 11, 87, 137). 
Moreover, the tail domain (Vt) changes conformation upon binding to certain ligands. Both 
F-actin (10, 120) and phosphatidylinositol 4,5-bisphosphate (PIP2) (10, 66) induce 
conformational changes in Vt upon binding which then drive oligomerization of Vt. In the 
case of F-actin, this oligomerization crosslinks F-actin filaments and is required for proper 
force transduction, focal adhesion (FA) maturation, and binding of some vinculin ligands (6, 
138). F-actin is a dynamic polymer. Therefore, studying Vt binding to F-actin and its 
conformational change upon binding are difficult to study by high resolution structural 
approaches, such as X-ray crystallography or nuclear magnetic resonance (NMR). Similar 
problems exist for studies with PIP2-binding and membrane insertion by Vt. Further 
complicating matters is the self-associative properties of Vt in the absence of ligand (127). 
With the development of Vt Q1018K as a Vt variant with a weaker affinity for self-
association, NMR becomes an available technique to study Vt (Chapter 4). NMR is 
particularly useful here, as it provides high-resolution structural and dynamic information. 
By studying the dynamics of Vt Q1018K in solution by NMR, we hope to learn something 
about the conformational changes that take place upon ligand binding.  
Vinculin is a highly conserved protein (139). In the middle of Vt helix 4, resides a 
conserved proline, P989, which generates a kink in the helix (Figure 5.1). Proline residues 
tend to disrupt helices, as they lack an amide proton and cannot form hydrogen bonds that 
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stabilize helical secondary structure. Moreover, prolines possess restricted backbone 
mobility relative to other amino acids. Prolines in the middle of α-helices are common in 
transmembrane proteins (140) and can also be found in some cytosolic proteins (141, 142), 
and are almost always associated with a kink in the helix. In some instances, the prolines are 
not required for the helix kink (141, 142), suggesting that other structural elements may 
promote kink formation. While P989 in vinculin is strictly conserved, the kink in Vt helix 4 
has yet to be probed for any structural or functional significance. 
Materials and Methods 
Protein expression and purification 
The plasmid for expression of Vt was generated by the Liddington lab (10) . The gene 
for chicken Vt (residues 879-1066) was placed into a pET15b vector for protein expression. 
All mutagenesis was performed using QuikChange site-directed mutagenesis (Stratagene, La 
Jolla, CA, USA) and the DNA sequence was verified by sequencing (Genewiz, RTP, NC, 
USA). Additionally, the Vt gene was cloned into the pQLinkH vector using BamHI and NotI 
as the 5’ and 3’ restriction endonucleases, respectively. pQLinkH, like pET15b, codes for an 
N-terminal histidine tag, but unlike pET15b, contains a TEV protease cleavage site instead of 
a thrombin cleavage site. 
To express Vt in bacteria, chemically competent BL21 DE3 E. coli with the Rosetta2 
plasmid (EMD Millipore, Billerica, MA, USA) were transformed with either vector and 
plated on LB plates containing ampicillin and chloramphenicol. A single colony was selected 
and grown overnight. The overnight growth was used to inoculate flasks with 1 L Luria 
Broth. Cells were grown at 37C until OD reached 0.6. Expression was induced with 250 μM 
IPTG, the incubator temperature was cut to 16-18 C, and cells were harvested after 16-20 
hours. To harvest, cells were pelleted via centrifugation and then resuspended in lysis buffer 
(20 mM Tris, 150 mM NaCl, 5 mM imidazole, and 2 mM β-mercaptoethanol (BME)). Cells 
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were lysed either with sonication or homogenization and the lysate was subsequently 
clarified by centrifugation at 25,000 × g for 45 minutes. His-tagged Vt proteins were first 
purified using Ni-NTA beads (Qiagen, Germantown, MD, USA). The lysate was applied to 
the beads, which were subsequently washed with lysis buffer. The beads were then washed 
with lysis buffer containing 60 mM imidazole. The protein was eluted with lysis buffer with 
500 mM imidazole.  
After purification by nickel column, proteins expressed in the pET15b system were 
dialyzed into thrombin cleavage buffer (20 mM Tris pH 7.5, 500 mM NaCl, 2 mM CaCl2, and 
5 mM BME) and their histidine tags cleaved by addition of thrombin (Sigma-Aldrich, St. 
Louis, MO, USA). Proteins were then further purified by ion exchange chromatography (S-
column) and size exclusion chromatography (S-200 superdex). 
For proteins expressed using the pQLinkH vector, after nickel affinity chromatography 
the N-terminal histidine tag was cleaved by the addition of TEV protease. The mixture was 
dialyzed overnight at room temperature into TEV cleavage buffer (20 mM Tris pH 7.5, 50 
mM NaCl, 5 mM BME). The protein mixture was then passed over Ni-NTA beads a second 
time to remove the histidine tag, TEV protease, and any contaminating proteins that bound 
to the Ni-NTA beads. After this step, ion exchange and size exclusion chromatography were 
used to obtain highly purified proteins samples (> 95% purity, as determined by SDS-gel 
electrophoresis). 
Circular dichroism 
Circular dichroism (CD) spectra were collected on a Jasco J-815 CD Spectrometer 
(JASCO, Easton, MD, USA). CD data were collected in 10 mM potassium phosphate, pH 5.5 
or pH 7.5, 50 mM Na2SO4, and 1 mM DTT at 25°C unless otherwise specified. For near-
ultraviolet (UV) measurements, protein was concentrated to 450 μM, while far-UV 
measurements were collected on protein at 5 μM. 
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Denaturation experiments were collected by tracking the CD of a sample at 222 nm as 
the temperature of the sample increased at a rate of 2°C min-1. 
NMR spectroscopy 
To make uniformly 15N-enriched Vt for NMR, Vt was expressed in M9 media with 
15NH4Cl as the sole nitrogen source. 15N-Vt was purified in the same manner as Vt from LB, 
exchanged into NMR buffer (10 mM potassium phosphate, pH 5.5, 50 mM NaCl, 0.1% NaN3, 
2 mM DTT, and 10% D2O), and concentrated to 30 μM. To generate uniformly 15N- and 13C-
enriched Vt, M9 media was used with 15NH4Cl and 13C-D-glucose as the nitrogen and carbon 
sources (Cambridge Isotope Laboratories, Tewksbury, MA, USA). Two-dimensional 
heteronuclear single quantum coherence (HSQC) spectra were collected on a Varian INOVA 
700 MHz spectrometer at 37°C. Three dimensional HNCACB and HNCO spectra for 
backbone assignments were collected on a Varian INOVA 700 MHz spectrometer equipped 
with a cryoprobe at 37°C. The HNCO was collected using 16 transients, 32 real increments in 
the 15N dimension, and 38 real increments in the 13C dimension. The HNCA was collected 
using 32 transients, 30 real time increments in the 15N dimension, and 52 real increments in 
the 13C dimension. Spectra were processed with NMRPipe (125) and analyzed with 
NMRViewJ (126). 
NMR relaxation experiments  
R1, R2, and heteronuclear {1H}-15N Nuclear Overhauser Effect (hetNOE) experiments 
(143) were collected on Varian INOVA 600 and/or 700 MHz magnets. The 600 MHz magnet 
was equipped with a room temperature probe and the 700 MHz magnet with a cryoprobe. 
The times used in the T1 and T2 experiments are reported in Table 5.1. All experiments were 
performed with 200 µM protein in NMR buffer at 37°C and collected in an interleaved 
fashion.  
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The Carr-Purcell-Meiboom-Gill (CPMG) was collected using an improved relaxation-
compensated sequence (144, 145) on the Inova 700 MHz spectrometer with a Bruker cold 
probe and console. The total CPMG period was 28 ms. In addition to a reference spectrum, 
13 total HSQC-type spectra were collected, two of which were duplicates. The delay times, τ, 
for these spectra ranged from 0.67 to 14 ms. These spectra were collected in an interleaved 
manner to limit the effect of any change in the sample or magnetic fields over time. 
Relaxation analysis 
Model-free analysis of 15N R1, R2, and NOE backbone relaxation data was performed 
using relxn2.2 (146, 147). The best fit for the isotropic rotational correlation time for Vt 
Q1018K was determined to be 11.86 ns/rad. To evaluate the effectiveness of using a model of 
rotational anisotropy, the program qfit (148) was employed using PDB file 1ST6. However, 
the data did not support the use of an anisotropic model for Vt tumbling, so an isotropic 
model was used. The N-H bond distance used was 1.0 Å and the 15N chemical shift 
anisotropy value used was -170. Models were selected based on Akaike’s information 
criterion (AIC) (149). Errors were estimated by 150 or more Monte Carlo simulations. 
CPMG data were analyzed with NMRViewJ (126). Peak intensities for each timepoint 
were determined. R2,eff was calculated using the following formula: 
ܴଶ,௘௙௙ ൌ െ1௥ܶ௘௟௔௫ ݈݊
ܫ
ܫ଴ 
where Trelax is the total CPMG pulse time, I is the intensity of the peak, and I0 is the intensity 
of the reference peak.  
Hydrogen exchange 
Samples for hydrogen exchange were prepared by exchanging Vt Q1018K into a 
deuterated buffer (10 mM potassium phosphate, pD 5.9, 50 mM NaCl, 0.1% NaN3, 2 mM 
DTT, 95% D2O) using a PD-10 column (GE Healthcare Life Sciences, Piscataway, NJ, USA). 
NMR spectra were collected on a Varian INOVA 700 MHz magnet using a fast-HSQC (150) 
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over the course of ten days at times reported in Table 5.2. Data were processed and fit to an 
exponential decay function using the Rate Analysis tool in NMRViewJ (126).  
CLEAN chemical exchange spectroscopy (CLEANEX) experiments (151, 152) were 
collected on a Varian INOVA 600 MHz magnet. Mixing times were 0, 15, 30, 55, 85, 125, 
180, and 300 msec. Data were processed and fit to an exponential function using the Rate 
Analysis tool in NMRViewJ (126). 
Actin co-sedimentation 
Actin co-sedimentation assays were performed as previously described (6, 103). G-
actin was polymerized by addition of 2X and 1X actin co-sedimentation buffer (10 mM Tris, 
pH 7.5, 100 mM KCl, 2 mM MgCl2, and 4 mM DTT)so that the final concentration of actin is 
45.6 μM and the buffer is at 1X. Polymerization was carried out for 30 minutes. Ten μL of 
100 μM Vt was mixed with enough actin and buffer to give the reported actin concentration 
in a total volume of 100 μL.  
Actin and Vt were incubated together at room temperature for 1 hour. The samples 
were then spun for 30 minutes at 150,000 × g. The supernatant was collected by pipetting 
and the pellet resuspended in an equal volume of actin co-sedimentation buffer. The 
supernatant and pellet fractions were run on a gel using SDS-PAGE, and band intensities 
were compared using ImageJ (104). The percentage of protein pelleted was calculated by 
dividing the intensity of the pellet band by the sum of the intensities of the pellet and 
supernatant bands. Values were adjusted to fit the percentages published previously (6, 43) 
by fitting to a binding curve and scaling the respective Kd values. 
To evaluate the ability of Vt to crosslink F-actin, the same procedure was followed, 
using only the 20 μM actin concentration point, and the spin was at 5,000 × g for ten 
minutes. The supernatant was pelleted off and the pellet resuspended. The fractions were 
run on a gel using SDS-PAGE and the actin bands quantified using ImageJ.  
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Fluorescence microscopy 
Fluorescence microscopy of actin bundles formed in the presence of Vt was performed 
as previously described (6, 153). Briefly, samples were prepared similarly to those used for 
the bundling co-sedimentation assay. The samples were then diluted 20-fold by the addition 
of actin polymerization buffer and Alexa Fluoro-488 phalloidin (Invitrogen, Carlsbad, CA, 
USA) was added to a final concentration of 1.5 μM. Samples were incubated with the 
fluorophore for five minutes and then 5 μL of the samples were placed on glass slides with a 
glass coverslip. Slides were observed with a Zeiss Axiovert 200M microscope with a 60× 
objective lens and images were collected using a Hamamatsu ORCA-ERAG digital camera. 
Negative-stain electron microscopy 
Samples were prepped by incubating 800 nM actin F-actin with 800 nM Vt (or Vt 
variant) on ice for ten minutes. Ten μL of sample was then applied to a copper grid covered 
by a thin glow-charged carbon foil and allowed to incubate on the grid at room temperature 
for one minute. The grid was then washed with 2% uranyl acetate for one minute by 
dropwise addition, blotted, and air dried. Grids were examined with a Philips CM12 TEM at 
80 kV and images were taken with a Gatan 2k × 2k SC200 CCD camera. 
Results 
Vt helices 1 and 4 are less solvent protected than other helices in the bundle 
With a Vt variant, Vt Q1018K, that exhibits decreased self-association, we were able to 
apply NMR techniques to evaluate protein dynamics (Chapter 4). Protein dynamics can 
reveal networks involved in allosteric motion; Vt, which changes conformation upon binding 
to F-actin and PIP2, likely has such dynamic networks. In the case of actin, we know that 
actin-binding involves helices 4 and 5 (Chapter 3) (103) and subsequent Vt dimerization 
involves the basic collar (Chapter 2)and the C-terminus (6, 115), so such a network would be 
expected to stretch from one surface to the other. Similar to NMR work with Vt (135), we 
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were unable to assign backbone resonances for the majority of residues in helix 1 in Vt 
Q1018K (Chapter 4). This indicates that helix 1 is undergoing conformational exchange on 
an intermediate NMR timescale. The lack of assignments limits any further analysis of helix 
1 dynamics by NMR. However, we wanted to evaluate the dynamics of the rest of the protein 
to better understand how Vt undergoes conformational change. 
One way to evaluate the dynamics of proteins is to measure the hydrogen-deuterium 
exchange (HDX) rates for backbone amides. These rates reflect the protection of the 
backbone amide hydrogen from solvent exchange, which is heavily influenced by the protein 
structure. If the protein samples a conformation in which the backbone amide hydrogen 
becomes less protected, such as the unfolding of a helix, this will be observed by an increase 
in the exchange rate. Vt Q1018K was subjected to both CLEANEX and standard HDX NMR 
experiments to measure these rates. 
Of the 150 assigned amide nitrogen and hydrogen pairs assigned in Vt Q1018K, 77 
were observable using real-time (RT) HDX techniques. Of these, 68 amide resonances fit 
well to an exponential decay. An additional 44 resonances were observable using CLEANEX. 
The remaining 29 residues could not be evaluated; either the rates of deuterium exchange 
were too slow for CLEANEX but too fast for HDX, or the resonances were in regions of the 
spectra where there was too much overlap to unequivocally determine the rate of exchange. 
Not surprisingly, the residues that were observable with CLEANEX reside primarily in loops 
or regions without defined secondary structure, while those observable by RT HDX reside 
primarily in the helices (Figure 5.2). The presence of residues in the helix bundle that are 
not observable by RT HDX suggests that the helices do undergo local unfolding at rates 
faster than 6 hr-1. 
Residues that were observed by RT HDX were tracked over the course of 18 days 
(Table 5.2), and the intensities of the 1H-15N peaks were fit to an exponential decay 
function, which provided the exchange rate, kex. By dividing the rate of exchange for the 
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amide in an unstructured protein (krc) by the rate of exchange in the folded protein, a 
protection factor (Pf) can be calculated (154). The free energy of exchange (and by extension, 
the structural change) is related to the log of the protection factor. The protection factors for 
residues are reported in Table 5.3. The average protection factor for residues in helices 
observable by RT HDX is reported in the final column. As shown in Table 5.3 and Figure 
5.2, helices 1 and 4 show the least protection of the five helices, suggesting that they undergo 
more frequent structural transitions to a state that de-protects the amide proton relative to 
helices 2, 3, and 5. This is congruent with the difficulty in assigning helix 1 residues (135) 
and the conformational mobility required in helices 1 and 4 to adopt the conformation seen 
upon binding to F-actin (Chapter 3). 
Vt Q1018K ps-ns backbone dynamics 
To further explore the dynamic properties of Vt, standard R1, R2, and {1H}-15N NOE 
NMR experiments were collected at two fields and the data analyzed to obtain the requisite 
parameters (Figure 5.3).These experiments probe NH backbone dynamics on a ps-ns 
timescale. The relaxation profiles for the majority of the residues that comprise the helix 
bundle, with high {1H}-15N NOE values and similar R1 and R2 values, indicate that these 
residues are not flexible on a ps-ns timescale. The unstructured regions have high R1 values, 
and, generally, lower R2 and {1H}-15N NOE values, indicative of residues with flexible 
backbone motions on a ps-ns timescale. The primary exceptions to this are the helix 3-helix 
4 loop, which has higher R2 rates, and the N-terminal strap. The N-terminal strap has {1H}-
15N NOE values indicative of residues that are not highly flexible, and supports the notion 
that the interactions between the strap and the helix bundle are relatively stable. The larger 
R2 values at the helix 3-helix 4 loop suggest that this portion of Vt Q1018K may undergo 
motions on a μs-ms timescale. 
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The helix 3-4 loop, the C-terminal arm, and helix 1 undergo μs-ms backbone motions 
In the current models for allostery (155, 156), many proteins sample their 
bound/active and unbound/unbound conformations independent of the presence of the 
allosteric ligand. In this model, conformational selection, the ligand alters the relative 
populations of each state. Transitions among these states often occur on a μs-ms timescale 
and may be detectable in the absence of a ligand. Vt undergoes an allosteric change upon 
binding to F-actin (120), and μs-ms motions detected in the helix 3-helix 4 loop may be 
related to this conformational change. 
The product of R1 and R2 is a good indicator of μs-ms motions, and limits the influence 
of rotational anisotropy on the metric (157). Residues with significantly larger products 
likely experience chemical exchange on the μs-ms timescale. The average product for 
residues in helices at 600 MHz is 15.9 s-2, while the average product for residues in helices at 
700 MHz is 13.2 s-2 (Figure 5.4). Residues with a product greater than the average by at 
least 2.5 times the error in the product at 600 MHz are K966, K970, Q971, and T979. Those 
that fit these criteria at 700 MHz are D882, A893, A921, L947, K970, Q971, R976, R978, 
N980, R1039, K1047, R1049, and D1051. The majority of these residues are clustered 
around the helix 3-helix 4 loop, with others in the C-terminus of helix 5, which is near the 
helix 3-helix 4 loop. 
With R1, R2, and {1H}-15N NOE values for Vt Q1018K at two fields, model-free analysis 
was performed to better characterize the protein dynamics (146, 147, 158, 159). Using 
relxn2.2, the six datasets were fit to 6 different models (Tables 5.4, 5.5) and AIC was used 
to select the best model. The results of the analysis are visualized in Figure 5.5. The order 
parameter, S2, reports on the flexibility of the backbone N-H bond vector. These values 
support what was seen in the NOE data, that the C-terminus of Vt Q1018K is flexible, as 
expected, but the N-terminus is less flexible. Additionally, the loops seem to be relatively 
flexible (and poorly fit), with the helix 4-helix 5 loop having the lowest average S2 order 
85 
parameter. Some of the residues fit best to models with a Rex component. These residues are 
mapped onto the structure of Vt in Figure 5.5, and are spread across the structure. 
However, residues with the largest Rex values are near the bottom of the helix bundle, 
suggesting that there may be μs-ms motions near the helix 3-helix 4 loop and the C-terminal 
arm. 
To further confirm the presence of exchange on a μs-ms timescale, CPMG data were 
collected at 700 MHz for Vt Q1018K. Put simply, CPMG pulses suppress the effects of 
chemical exchange on a μs-ms timescale. The more frequent the CPMG pulses, the better the 
effects of µs-ms motions are suppressed, and the effective R2 (R2,eff) of the nucleus decreases. 
Thus, if the nucleus (and its residue) is undergoing chemical exchange on a μs-ms timescale, 
a decrease in the R2,eff is observed as the CPMG pulse frequency increases. The average R2,eff 
for the four longest delay times (five total data points) was subtracted from the average R2,eff 
for the four shortest delay times (five total data points). The dispersion curves for residues 
that exhibited a difference in the average R2,eff greater than 4 s-1 were evaluated and residues 
with strong outliers that exaggerated the average were discarded. The remaining 13 residues 
are shown in Figure 5.6. As with the model-free analysis and the R1R2 product, the majority 
of these residues reside near the helix 3-helix 4 loop. The relatively high error is due, to the 
low concentration (200 μM) of Vt Q1018K, used to limit self-association, and the loss of 
signal to relaxation. 
Mutation of P989 likely disrupts the kink in helix 4 
The presence of μs-ms motions near the lower actin binding site at the helix 3-helix 4 
loop (103, 121, 123) suggested that these motions might be involved or related to the 
conformational change that takes place in Vt when it binds F-actin (10, 120). The kink in 
helix 4 caused by P989 (Figure 5.1) was identified as a potential structural feature that may 
facilitate such motions. We postulated that removal of the helix 4 kink would likely disrupt 
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the μs-ms motions near the lower F-actin binding site and influence the ability of Vt to adopt 
the appropriate conformation for crosslinking actin filaments. 
To test this, P989 was mutated to alanine (P989A) to straighten helix 4. Alanine 
introduces an amide proton to form the missing hydrogen bond with C985 and has the 
highest helical propensity of the 20 native amino acids (160). CD was the first technique 
applied to evaluate the structural consequences of the Vt P989A mutation. As shown in 
Figure 5.7, the far-UV spectra for Vt P989A is similar to that obtained for Vt (Figure 5.7), 
suggesting that the mutation does not significantly alter the helical character of Vt. This was 
somewhat expected, as altering the kink in a single helix is unlikely to significantly 
contribute to the relative signal for an α-helical protein. Additionally, the near-UV spectra 
for Vt and Vt P989A are similar as well, suggesting that the mutation does not disrupt the 
packing of W912 with W1058. This packing interaction indicates that the C-terminus of Vt is 
packing normally against the helix bundle and the helix 1-helix 2 loop; it is a reasonable 
proxy for proper tertiary structure (127). However, the CD thermal denaturation curve 
shows an increase in the Vt P989A denaturation midpoint of 4C relative to Vt, yet it unfolds 
in a less cooperative manner. The decrease in cooperativity and increase in thermal stability 
indicate that P989A is likely adopting a slightly different conformation from Vt, supporting 
the expectation that helix 4 in Vt P989A is no longer kinked.  
To further evaluate the structural changes induced by the P989A mutation, a 1H-15N 
2D HSQC was collected with Vt P989A/Q1018K (Figure 5.8). The introduction of the 
P989A mutation caused at least 45 (24.4%) 1H-15N peaks to significantly shift. These shifted 
signals were found in helices 2-5, indicating that the effects of the P989A mutation were not 
restricted to residues in the immediate vicinity of 989. Because of the large number of shifts, 
assignments from Vt Q1018K could not be used for Vt P989A/Q1018K. Hence, 3D HNCACB 
and CBCACONH experiments were run to assign the HN, N, Cα, and Cβ chemical shift 
values for Vt P989A/Q1018K. Only 79.5% of the non-proline Cα resonance assignments were 
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obtained for Vt P989A/Q1018K, as many of the residues preceding A989 could not be 
assigned (Figure 5.8). The difficulty in assigning these residues is due primarily to their 
weak signals, suggesting that these signals are line broadened and undergo conformational 
exchange between two or more states on the intermediate NMR time scale at 700 MHz. 
Additionally, the Cα and Cβ shifts for the residues at the end of helix 3 are significantly 
shifted compared to the signals in Vt Q1018K. Though these resonances shifted, they still 
were indicative of resonances from residues in an α-helix, suggesting that helix 3 maintains 
its helicity. These data suggest that the P989A mutation removes the helix 4 kink, potentially 
changing the dynamics at the helix 3-helix 4 loop. 
Mutation of P989 changes the backbone dynamics of Vt 
To further explore how the P989A mutation affects Vt backbone dynamics, R1, R2, and 
{1H}-15N NOE data were collected for Vt P989A/Q1018K on a 700 MHz magnet (Figure 
5.9). Upon comparison to Vt Q1018K, there are minimal changes in the relaxation rates and 
NOE ratios. The largest difference is the decreased R2 values at the helix 3-helix 4 loop in Vt 
P989A/Q1018K, which results in a decreased R1R2 product for these residues (Figure 5.9), 
suggesting that the P989A mutation disrupts the µs-ms time scale dynamics at the helix 3-
helix 4 loop, likely changing the timescale of or eliminating these motions. Moreover, these 
results indicate that the helix 4 kink contributes to µs-ms timescale motions associated with 
the helix 3-helix 4 loop. In contrast, the higher R1R2 values observed for residues 893 and 
896 are maintained, suggesting that μs-ms motions associated with these residues are not 
significantly disrupted by the P989A mutation and are unlikely coupled to motions at the 
helix 3-helix 4 loop. 
Mutation of P989 does not significantly affect the ability to bind or bundle F-actin 
P989 resides near the F-actin binding interface (103) and creates a kink in helix 4. As 
this helix plays a key role in actin-binding , the actin binding and bundling properties of Vt 
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P989 were evaluated. The ability of Vt P989A to bind or bundle F-actin is similar to that 
observed for Vt (Figure 5.10). These data provide further support for the cryo-EM model 
(Chapter 3) that shows helix 4 is straight when Vt binds to F-actin. 
Mutation of Vt P989 changes the morphology of crosslinked actin filaments 
The loss of the helix 4 kink did not change the affinity of Vt P989A for F-actin or its 
ability to quantitatively crosslink filaments relative to Vt (Figure 5.10). We wanted to test if 
these changes caused structural changes in the Vt:actin interactions that would not be 
observed by an actin co-sedimentation assay. To that end, Vt and Vt P989A were incubated 
with F-actin, phalloidin was added to label actin, and then the sample was evaluated with a 
fluorescent microscope. As expected, in the absence of Vt, the actin remains polymerized, 
but is not bundled. Addition of Vt resulted in actin bundles, crosslinked by Vt (Figure 5.11) 
(6). Addition of Vt P989A produced actin bundles, in agreement with the co-sedimentation 
results. However, the actin bundles crosslinked by Vt P989A tended to be shorter and 
thinner. The resolution limitations of fluorescence microscopy (hundreds of nanometers) 
prevented a more detailed description of the structural differences. 
To overcome these limitations, negative-stain EM was used to characterize the F-actin 
bundles at a higher resolution. F-actin, in the absence of Vt, did not form crosslinked 
filaments (Figure 5.12). Addition of Vt resulted in actin bundles that were comprised 
primarily of parallel actin fibers. The addition of Vt P989A still produced actin bundles, but 
these bundles tended to have an increased number of cross-over events, where the filaments 
wound over each other. Other bundles tended to fray or splay out at the ends. These results 
suggest that Vt P989A slightly alters the conformation of Vt bound to F-actin and/or the Vt 
dimer responsible for crosslinking F-actin such that the actin filaments no longer run 
parallel to each other. These slight structural differences are not distinguishable by actin co-
sedimentation, which relies on a difference in the size of the crosslinked actin bundles. 
Instead, the bundle architecture is observable by negative-stain EM. These findings suggest 
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that conformational sampling between two or more states on the µs-ms timescale at the 
helix 3-helix 4 loop and nearby residues is involved in the Vt:F-actin interaction. One or 
more of these conformers may contribute to or promote the conformational changes that 
take place when Vt binds F-actin and subsequently dimerizes. Disruption of these 
conformations or the ability to sample them by the P989A mutation may cause the observed 
changes in the actin bundle geometry we observed. 
Discussion 
Protein function is regulated by both the protein’s structure and dynamics. Vt’s ability 
to bind and bundle F-actin relies on its structural plasticity (Chapter 3). Vt changes 
conformation upon binding to F-actin, which is required for F-actin crosslinking (10, 120), 
but the distinct structural and dynamic details of this transition are only beginning to be 
understood. The work presented here begins to address some of these gaps. 
One of the most surprising observations is that, compared to the C-terminus of Vt, 
residues in the N-terminus have higher order parameters (S2) and thus fewer motions on the 
ps-ns timescale (Figure 5.5). X-ray structures of Vt suggest that the strap can adopt 
multiple conformations (2, 10, 133) while packing against the helix bundle. These results 
support the notion that the N-terminal strap interacts strongly with the Vt helix bundle, and 
that the different conformations for the strap do not exchange on a ps-ns timescale. This is 
further supported by the fact that removal of the N-terminal strap increases the affinity of Vt 
for both F-actin and PIP2 (43), suggesting that release of the strap from the helix bundle has 
an energy cost. In the case of PIP2-binding, release of the strap increases the exposure of the 
basic collar binding site (Chapter 2) (40), and in F-actin binding, it likely decreases the 
energy cost for helix 1 partitioning away from the helix bundle.  
Helices 1 and 4 of Vt appear to be the most dynamic of the five helices in the helix 
bundle. The majority of residues in helix 1 have eluded observation by NMR, likely due to 
conformational exchange of helix 1 on an intermediate NMR timescale. This is supported by 
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the observation that helix 1 is partitioned from the helix bundle when Vt binds to F-actin 
(Chapter 3). Indeed, it is quite possible that this unfolding event occurs in the absence of 
actin and that the partitioned conformation is one of the conformations being sampled by 
helix 1 that prevents backbone assignment. Direct observation of this event has been 
difficult, however, and more work is required, possibly by electron paramagnetic resonance 
or fluorescent studies, to confirm this hypothesis. Heilx 4 is also dynamic. Though the 
majority of its residues are observable by NMR, its backbone amides have the lowest average 
protection factor compared to residues in the remaining helices as measured by HDX. This 
indicates that helix 4 is undergoing more frequent local unfolding events than the helices 2, 
3, or 5. Additionally, backbone dynamics on the μs-ms timescale at the helix 3-helix 4 loop, 
which are ablated by the P989A mutation, suggest that the N-terminal portion of helix 4 
undergoes conformational exchange that is not an unfolding event. It is quite intriguing that 
these two dynamic helices, 1 and 4, feature prominently in the conformational changes that 
take place when Vt binds F-actin (Chapter 3). As mentioned earlier, helix 1 partitions from 
the helix bundle upon actin binding and helix 4 significantly straightens, losing its kinked 
conformation. 
Both the model-free analysis and the CPMG data suggest that many other residues 
near and in the C-terminal arm possess backbone μs-ms motions. The presence of these 
motions provide for the possibility of a dynamic network that extends from the helix 3-helix 
4 loop back to the helix 1-helix 2 loop. The decreased R1R2 product of the helix 3-helix 4 loop 
residues in Vt P989A suggests that such a network is also dependent upon the kink in helix 4 
and the flexibility it provides. Further characterization by collecting CPMG data at additional 
field strengths is required to better quantitate these backbone motions and the existence of a 
possible dynamic network. 
The CPMG experiment, in addition to reporting on internal protein motions, may also 
be reporting on the dimerization of Vt (described in Chapter 4) (10, 127). Its ability to see 
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very small populations means that, even using Vt Q1018K, there may be signal coming from 
a monomer/dimer equilibrium. However, the data do not support this. The R2,eff values for 
residues at the dimer interface are not significantly different across the CPMG frequencies 
used. Specifically, S1016 and T962, residues with HN chemical shifts that report on 
dimerization, have flat dispersion curves. This suggests that, at the low concentrations used, 
the contribution to relaxation dispersion from the monomer/dimer equilibrium is negligible. 
With the collection of dispersion data at other field strengths, this potential complication 
will be addressed further. 
The similarities between sites that show μs-ms backbone dynamics and those that 
show lower protection factors with sites where Vt changes conformation upon binding to F-
actin are intriguing. These similarities suggest that these µs-ms backbone dynamics may 
play a role in actin-binding and that Vt may sample the actin-bound conformation in the 
absence of F-actin. That this conformation has only recently been observed, and only in the 
presence of F-actin suggests that, if Vt does sample the actin-bound conformation in the 
absence of F-actin, only a small fraction of Vt samples it at a given time. If this is the case, it 
would mean that this conformation could be studied in the absence of F-actin by techniques 
that are sensitive to small populations of a sample, such as NMR or electron paramagnetic 
resonance.  
Helix 4 and the C-terminal arm, sites of local unfolding and µs-ms backbone motions, 
mediate the autoinhibitory interaction between vinculin head and Vt (10, 28). These motions 
may be suppressed when vinculin is in its autoinhibited conformation, decreasing the 
entropy of the closed conformation and priming vinculin for activation. The kink in Vt helix 
4 is a perfect candidate for such a mechanism, as we have now observed it in two distinct 
conformations. In the context of the autoinhibited vinculin structure, the proline-induced 
kink allows for Vt helix 4 to participate in two different head:tail interfaces (Figure 5.13) 
(2). However, upon binding to F-actin, the kink is no longer present in helix 4 (Chapter 3). 
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Given these findings, we would predict that vinculin P989A, which should remove the kink 
and straighten helix 4, will show weaker autoinhibitory interactions with the head domain, 
thereby increasing the population of active vinculin in cells. In addition to mediating 
different conformations in helix 4, the kink also plays a role in allowin μs-ms backbone 
dynamics at the helix 3-helix 4 loop. However, the dramatic difference in F-actin bundling 
architecture induced by Vt P989A was somewhat surprising. The affinity of Vt P989A for F-
actin and its propensity to crosslink actin filaments remains unchanged, suggesting that the 
Vt conformation induced by the P989A mutation is conducive to these functions. Yet, the 
actin bundles formed by Vt P989A exhibit an altered structure; the filaments in these 
bundles do not appear parallel to each other. This altered geometry suggests that the P989A 
mutation somehow disrupts or alters the conformational change in Vt that drives actin-
bundling geometry. This could be the result of disrupting the µs-ms backbone motions at the 
helix 3-helix 4 loop (Figure 5.9), a function of changes in the helix bundle structure 
(Figures 5.7, 5.8), both, or some other mechanism. A better understanding of the Vt dimer 
responsible for crosslinking is likely required before this question can be fully addressed. 
However, the conservation of P989 indicates that the kinked nature of helix 4 is important in 
vinculin function.  
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T1 (s) T2 (ms) 
Order 600 MHz 700 MHz 600 MHz 700 MHz 
1 1.304202 0.114202 110.5664 7.968 
2 0.024202 3.514202 47.3856 103.584 
3 0.114202 1.454202 63.1808 39.84 
4 1.604202 0.369202 31.5904 15.936 
5 0.304202 2.854202 15.7952 71.712 
6 1.004202 1.854202 78.976 47.808 
7 0.704202 0.654202 71.0784 31.872 
8 0.854202 2.354202 134.2592 55.776 
9 0.554202 0.984202 94.7712 23.904 
10 1.304202 0.114202 110.5664 39.84 
11 0.114202 2.854202 31.5904 7.968 
12 0.704202 0.984202 71.0784 71.712 
 
Table 5.1. Times of the relaxation periods used in R1 and R2 NMR experiments.  
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Experiment number time (min) time (hr) 
1 19.5 0.325 
2 29.13333 0.485556
3 40 0.666667
4 55 0.916667
5 70 1.166667
6 85 1.416667
7 100 1.666667
8 120 2 
9 140 2.333333
10 165 2.75 
11 190 3.166667
12 220 3.666667
13 260 4.333333
14 310 5.166667
15 370 6.166667
16 460 7.666667
17 550 9.166667
18 670 11.16667
19 816 13.6 
20 962 16.03333
21 1108 18.46667
22 1254 20.9 
23 1400 23.33333
24 1460 24.33333
25 1845 30.75 
26 1880 31.33333
27 2333 38.88333
28 2873 47.88333
29 4311 71.85 
30 8963 149.3833
31 13067 217.7833
32 15821 263.6833
33 25994 433.2333
 
Table 5.2. Hydrogen exchange times. 
The times since addition of Vt Q1018K to a PD-10 column to the midpoint for each 
fast-HSQC experiment are listed above. These times were used when fitting the data to an 
exponential decay curve. 
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Residue kex (103 min-1) krc (min-1) Pf ln(Pf) Average ln(Pf)
884 0.35 ± 0.04 10.64 30789 ± 3125 10.33 ± 0.1  
Helix 1 8.69 ± 0.13 
900 8.7 ± 0.49 47.35 5440 ± 306 8.6 ± 0.06  
901 7.41 ± 0.55 48.46 6536 ± 480 8.79 ± 0.07  
Helix 2 10.85 ± 1.44 
917 2.09 ± 0.24 171.93 82444 ± 9657 11.32 ± 0.12  
921 0.54 ± 0.02 37.61 69656 ± 2322 11.15 ± 0.03  
923 0.81 ± 0.09 34.30 42273 ± 4697 10.65 ± 0.11  
924 1.02 ± 0.84 59.61 58446 ± 48132 10.98 ± 0.82  
925 1.35 ± 0.21 9.89 7321 ± 1116 8.9 ± 0.15  
928 1.87 ± 0.15 48.46 25907 ± 2044 10.16 ± 0.08  
931 0.1 ± 0.04 48.46 504756 ± 189284 13.13 ± 0.38  
932 3.03 ± 0.43 13.50 4457 ± 634 8.4 ± 0.14  
934 0.43 ± 0.01 113.59 261494 ± 8307 12.47 ± 0.03  
935 1.13 ± 0.02 90.23 79568 ± 1684 11.28 ± 0.02  
937 7.12 ± 0.14 4.63 650 ± 13 6.48 ± 0.02  
938 4.76 ± 0.11 32.76 6885 ± 161 8.84 ± 0.02  
Helix 3 9.95 ± 2.29 
948 17.38 ± 0.55 4.32 249 ± 8 5.52 ± 0.03  
949 16.32 ± 1.31 25.43 1558 ± 125 7.35 ± 0.08  
950 0.9 ± 0.02 248.51 275944 ± 5331 12.53 ± 0.02  
951 0.13 ± 0.02 133.46 1059209 ± 151316 13.87 ± 0.14  
952 0.62 ± 0.1 34.30 54975 ± 8458 10.91 ± 0.15  
953 0.28 ± 0.01 26.79 94407 ± 4191 11.46 ± 0.04  
955 0.26 ± 0.01 22.15 86655 ± 4679 11.37 ± 0.05  
956 2.04 ± 0.05 34.30 16816 ± 396 9.73 ± 0.02  
957 1.6 ± 0.1 49.59 30952 ± 1855 10.34 ± 0.06  
960 14.72 ± 0.2 9.46 643 ± 9 6.47 ± 0.01  
961 0.12 ± 0.01 5.92 49302 ± 5177 10.81 ± 0.11  
962 0.28 ± 0.01 23.19 83128 ± 3039 11.33 ± 0.04  
963 2.02 ± 0.06 71.67 35552 ± 1058 10.48 ± 0.03  
964 0.53 ± 0.05 16.42 30748 ± 2764 10.33 ± 0.09  
966 0.3 ± 0.03 34.30 114349 ± 11435 11.65 ± 0.1  
967 0.97 ± 0.02 17.79 18417 ± 458 9.82 ± 0.02  
968 0.05 ± 0.02 5.92 128057 ± 44903 11.76 ± 0.35  
969 0.1 ± 0.01 27.25 262516 ± 24279 12.48 ± 0.09  
970 3.9 ± 0.11 34.30 8801 ± 260 9.08 ± 0.03  
971 40.43 ± 6.89 56.93 1408 ± 240 7.25 ± 0.17  
972 0.13 ± 0.01 248.51 1872389 ± 164284 14.44 ± 0.09  
Helix 4 8.57 ± 2.05 
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977 13.65 ± 1.52 11.62 852 ± 95 6.75 ± 0.11  
980 2.67 ± 0.06 184.23 68999 ± 1551 11.14 ± 0.02  
981 4.75 ± 0.28 20.67 4354 ± 253 8.38 ± 0.06  
983 8.45 ± 0.42 26.63 3153 ± 156 8.06 ± 0.05  
984 0.83 ± 0.07 11.89 14418 ± 1154 9.58 ± 0.08  
985 0.86 ± 0.02 113.59 132319 ± 3610 11.79 ± 0.03  
986 16.43 ± 1.78 47.88 2915 ± 316 7.98 ± 0.11  
988 5.99 ± 0.5 11.62 1942 ± 163 7.57 ± 0.08  
991 8.16 ± 0.27 11.10 1361 ± 45 7.22 ± 0.03  
992 13.33 ± 0.54 51.92 3896 ± 157 8.27 ± 0.04  
997 22.13 ± 3.44 9.23 417 ± 65 6.03 ± 0.16  
998 10.59 ± 0.16 5.83 550 ± 9 6.31 ± 0.02  
999 0.24 ± 0.05 54.37 227003 ± 48326 12.33 ± 0.21  
Helix 5 10.66 ± 2.05 
1017 0.79 ± 0.12 26.93 34259 ± 5230 10.44 ± 0.15  
1018 3.41 ± 0.23 27.04 7931 ± 540 8.98 ± 0.07  
1024 8.02 ± 0.16 4.63 577 ± 11 6.36 ± 0.02  
1027 0.36 ± 0.02 78.59 218298 ± 14553 12.29 ± 0.07  
1028 3.28 ± 0.07 43.19 13176 ± 283 9.49 ± 0.02  
1029 1.01 ± 0.14 184.23 181683 ± 25801 12.11 ± 0.14  
1030 0.08 ± 0.01 20.67 275608 ± 28663 12.53 ± 0.1  
1031 5.19 ± 0.24 22.66 4364 ± 202 8.38 ± 0.05  
1032 1 ± 0.05 55.64 55524 ± 2992 10.92 ± 0.05  
1033 2.34 ± 0.05 139.75 59722 ± 1225 11 ± 0.02  
1035 0.02 ± 0.01 24.85 1294349 ± 687623 14.07 ± 0.53  
1037 0.12 ± 0.01 25.24 211367 ± 21243 12.26 ± 0.1  
1038 0.04 ± 0.01 11.89 275340 ± 57362 12.53 ± 0.21  
1039 0.15 ± 0.01 32.76 215815 ± 17060 12.28 ± 0.08  
1040 0.53 ± 0.02 22.40 41943 ± 1885 10.64 ± 0.04  
1041 0.13 ± 0.01 29.65 221611 ± 21863 12.31 ± 0.1  
1042 0.53 ± 0.01 13.50 25589 ± 611 10.15 ± 0.02  
1043 15.31 ± 0.28 29.65 1936 ± 35 7.57 ± 0.02  
1044 10.78 ± 0.84 37.61 3491 ± 272 8.16 ± 0.08  
 
Table 5.3. Protection factors for Vt Q1018K derived from NMR hydrogen exchange data. 
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Model Parameters Fit 
1 S2, τe 
2 S2, τe, τm 
3 S2, τe, CSA 
4 S2, τe, τm, CSA 
5 S2, Rex 
6 S2, τe, Rex 
 
Table 5.4. Models used for Lipari-Szabo model-free fitting of R1, R2, and {1H}-15N NOE 
datasets. 
The parameters fit for each of the different models using the R1, R2, and {1H}-15N NOE 
datasets are shown. S2 is the order parameter and describes the rigidity of the N-H bond 
vector relative to the protein, τm is the tumbling time of the molecule, τe is the rate of internal 
motion on a ps-ns timescale, chemical shift anisotropy (CSA) describes the anisotropic 
variation in the surrounding magnetic field of the 15N nucleus, and Rex is the relaxation 
component due to conformational exchange, often on a μs-ms timescale.  
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Residue Model 
881 3
882 2
884 3
885 3
887 4
888 4
889 2
890 2
891 2
892 2
893 6
894 3
895 3
896 4
900 6
901 5
902 1
915 2
916 1
917 4
921 5
923 3
924 4
925 5
926 5
928 4
929 1
930 3
931 5
932 3
933 5
934 3
935 3
937 3
938 3
939 3
940 3
941 3
943 2
944 3
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945 3
946 4
947 6
948 2
949 3
950 1
951 2
952 2
953 3
954 3
955 4
956 2
957 4
958 3
959 4
960 2
961 6
962 1
963 2
964 3
965 4
966 3
967 2
968 5
969 4
970 6
971 6
972 2
973 2
974 2
975 5
976 6
977 2
978 4
979 4
980 2
981 3
982 4
983 3
984 3
985 4
100 
986 2
987 3
988 3
990 4
991 1
992 3
993 4
996 4
997 3
998 3
999 4
1003 3
1004 4
1005 2
1006 3
1007 3
1008 2
1009 1
1010 3
1011 2
1012 3
1013 4
1014 2
1015 2
1016 1
1017 2
1018 2
1020 5
1023 3
1024 5
1025 5
1026 4
1027 5
1028 2
1029 2
1030 5
1031 5
1032 2
1033 6
1034 2
1035 1
101 
1037 2
1038 5
1039 6
1040 5
1041 1
1042 2
1043 2
1044 4
1045 1
1046 2
1047 1
1048 2
1049 3
1050 2
1051 2
1052 3
1053 2
1054 2
1055 2
1056 3
1057 3
1059 4
1061 2
1062 2
1064 2
1065 4
1066 2
 
Table 5.5. Models chosen by AIC to fit each residue. 
 Each residue for which NMR data was obtained was fit to one of six models (Table 
5.4). The model was chosen based on the AIC for the fit of each model.   
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Figure 5.1. Vt helix 4 is kinked by the presence of proline 989. 
The presence of proline 989 in the middle of helix 4 induces a kink in the helix. On the 
left is Vt, with helix 4 in pink and P989 in sticks. On the right is a magnified image of P989. 
Also shown is cysteine 985, and the missing hydrogen bond between P989 and C985 is 
shown with a dashed line. 
  
103 
 
 
Figure 5.2. Hydrogen exchange rates for Vt Q1018K. 
 Vt residues are grouped according to hydrogen exchange rate. Residues in red 
undergo amide proton-deuterium exchange on a time scale slow enough to be observed by 
RT HDX. Residues in yellow exchange fast enough to be detected by CLEANEX. Residues in 
orange exchange too quickly to be observed by RT HDX but too slowly to be observed by 
CLEANEX. Residues in black are unassigned.  
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Figure 5.3. R1, R2, and {1H}-15N NOE values for Vt Q1018K at two separate fields. 
The results of the R1 (A), R2 (B), and {1H}-15N NOE (C) NMR experiments are plotted 
above as a function of the Vt residue. Increases in R1 occur at loops, as do the decreases in 
R2. Heteronuclear NOE values decrease at the C-terminus, as expected, but are higher than 
would be expected for the unstructured N-terminus. 
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Figure 5.4. The R1R2 product for Vt Q108K at two fields. 
The R1R2 product as a function of Vt Q1018K residue is plotted above (A). Residues 
with significantly larger products are mapped onto the Vt structure (B, PDB file 1ST6). Those 
with a significantly larger product at 600 MHz are highlighted in blue, at 700 MHz in red, 
and at both fields in purple. The majority of these residues are located near the helix 3-helix 
4 loop. 
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Figure 5.5. Analysis of relaxation data by mode-free formalism. 
The results of the analysis with relxn2.2 are shown. The S2 parameter provides 
information on backbone flexibility on the ps-ns timescale (A). A value of 1 corresponds to a 
completely rigid bond, while a value of 0 corresponds to a vector that is completely free to 
sample any orientation. Rex is plotted for residues whose data are fit best using model 5 or 6 
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(B). These residues are highlighted on Vt (C, PDB file 1ST6). Residues with Rex > 2 s-1 are 
colored in bright red, while those that show Rex < 2 s-1 are pink. Unassigned residues are 
colored in black.  
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Figure 5.6. NMR CPMG results for Vt Q1018K. 
Dispersion curves for different groups of residues collected on a 700 MHz magnet are 
shown (A). Blue, red, and purple residues all show changes in R2,eff as a function of the 
frequency of the CPMG pulse train. Green residues show no change in R2,eff. These residues 
are mapped onto Vt (B, PDB file 1ST6). 
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Figure 5.7. CD data for Vt P989A. 
Shown are the near-UV CD (A), far-UV CD (B), and thermal denaturation (C) data for 
Vt and Vt P989A. Vt is in black, with Vt P989A in purple. While near- and far-UV CD data  
110 
for WT Vt and P989A Vt significantly different, thermal denaturation profiles indicate that 
Vt P989A unfolds in a less cooperative manner than Vt, yet has a slightly higher 
denaturation midpoint.   
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Figure 5.8. NMR of Vt P989A. 
Shown is a 2D 1H-15N HSQC of Vt P989A/Q1018K (purple) overlaid with Vt Q1018K 
(black) (A). Vt Q1018K NH peaks that shift in the context of a P989A mutation are mapped 
onto the Vt structure (PDB file 1ST6) on the left in magenta (B). Unassigned residues are in 
black, and P989 is in blue. The ribbon diagram on the right shows residues with a significant 
change in their Cα and Cβ shifts (orange). Residues lacking assignments for Vt 
P989A/Q1018K but were assigned in Vt Q1018K are shown in green. 
112 
 
Figure 5.9. R1, R2, {1H}-15N NOE, and R1R2 values for Vt P989A/Q1018K. 
The R1 (A), R2 (B), {1H}-15N NOE (C), and R1R2 (D) values for Vt P989A/Q1018K 
collected at 700 MHz are shown compared to those for Vt Q1018K. These data are quite 
similar for the two constructs for most residues. However, for residues 970-980, the R2 rates 
are lower for Vt P989A/Q1018K than for Vt Q1018K. 
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Figure 5.10. Actin binding and bundling by Vt P989A is similar to Vt. 
Vt P989A (purple) is able to bind (A) and bundle (B) F-actin similarly to Vt (black) 
when evaluated by standard actin co-sedimentation assays. Averages are shown (n=3) and 
the errors are the standard deviations.  
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Figure 5.11. Fluorescent microscopy of F-actin bundles formed by Vt and Vt P989A. 
Shown are representative images of F-actin stained with phalloidin. The addition of Vt 
results in crosslinking of the actin filaments into bundles. The addition of Vt P989A results 
in crosslinked filaments, though the bundles are generally shorter in appearance. The scale 
bar is 30 μm in length. 
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Figure 5.12. Negative-stain EM of F-actin crosslinked by Vt and Vt P989A. 
Shown are representative negative-stain EM images of F-actin, F-actin crosslinked by 
Vt, and F-actin crosslinked by Vt P989A, respectively. Without Vt, F-actin filaments are not 
crosslinked. Vt or Vt P989A are able to crosslink actin filaments. However, bundles of F-
actin crosslinked by Vt P989A are more likely to be wound (left) or to splay out (right) than 
those crosslinked by Vt. 
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Figure 5.13. Residues with μs-ms backbone dynamics are present at the vinculin head:tail 
interface. 
Shown is the structure of full-length vinculin (PDB file 1ST6) in green, with Vt in the 
color scheme from Figure 5.6. Residues in black are unassigned, and residues in magenta, 
red, and blue exhibit significant changes in their R2,eff values as a function of the frequency 
of the CPMG pulses and are sites of μs-ms backbone motions. These sites are close to the 
lower vinculin head:tail interface. 
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Chapter 6: Conclusions and Future Directions 
 
As a scaffold protein with a litany of binding partners, vinculin provides a difficult 
challenge for scientists wishing to understand the biological function of each interaction it 
undergoes. Deletion of a domain disrupts all of the binding interactions facilitated by the 
deleted domain. Deletion of significant portions of a domain may perturb a nearby binding 
site or alter the structure of the domain, making it incapable of binding a ligand at a site 
distant from the deletion. Mutations are the best tool, but they can cause the same problems 
as a partial domain deletion if the appropriate controls are not performed. The use of 
mutations is made easier when a good structural model exists from which to design specific 
point mutations. Further complicating this problem for vinculin are the technical difficulties 
associated with developing good structural models with two of the tail ligands, 
phosphatidylinositol 4,5-bisphosphate (PIP2) and F-actin.  
To overcome some of these challenges, we applied a variety of biophysical, 
biochemical, and computational techniques to develop better models for the interaction of 
Vt with F-actin and PIP2 (103). Through the serendipitous discovery of the actin-binding 
deficiencies of Vt I997A and V1001A and the application of negative-stain EM and discrete 
molecular dynamics (103), vinculin tools were developed to study the biological 
consequences of F-actin-binding by vinculin (103, 124). By using these tools, we have shown 
that the vinculin:actin interaction is one of, but not the only way in which vinculin regulates 
actin flow, both at focal adhesions and in the lamellipodium (124). This influence over the 
flow rate of F-actin at focal adhesions and in the lamellipodium regulates the number, 
growth, and size of these focal adhesions (103, 124). Additionally, the binding of vinculin to 
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F-actin is required for effective cell spreading, reinforcement at focal adhesions (103), 
generation of traction forces, and cell migration (123).  
Similarly, defining the PIP2 binding site on Vt has required the utilization of both 
biochemical and computational approaches. These data support the model outlined in 
Chapter 2, in which PIP2 binds to Vt at the basic collar while the basic ladder mediates 
interactions with the lipid bilayer. A crystal structure of Vt bound to a short chain PIP2 
molecule was recently published that calls these findings into question (40), proposing that 
both the basic collar and basic ladder are involved in direct PIP2 binding. However, the 
structure was determined with a Vt mutant, R1060A, in the absence of a lipid bilayer; it 
provides little help in understanding what a Vt:PIP2 complex may look like at a membrane. 
Our data agree well with the biochemical data from Chinthalapudi et al. (40), but we think a 
structural model that utilizes a lipid bilayer is a better interpretation of the data. 
Both the Vt:actin and Vt:PIP2 models described in this dissertation have room for 
improvement. In the case of the Vt:actin model, cryo-EM will likely prove to be the most 
useful approach. An even higher-resolution model of the Vt:actin interaction would, ideally, 
provide information about specific sidechain interactions at the interface and resolve the 
location of the residues that make up the N-terminal strap, helix 1, and the C-terminus of Vt. 
Such a model would require the use of the latest cryo-EM imaging equipment and 
technology, which have been used to develop structural models at near-atomic resolution (< 
4Å) (161-164). Another technical barrier limiting the resolution of the Vt:actin model is the 
tendency of Vt to disengage from the actin filament during freezing of the sample. By 
changing buffer conditions and possibly the freezing technique, actin filaments should 
remain more saturated with Vt. This greater saturation will provide more complete data sets, 
leading to a higher-resolution model. 
Such a high-resolution model would provide a strong starting-point towards modeling 
a structure that has been extremely elusive: the Vt dimer responsible for crosslinking F-actin 
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filaments. A higher-resolution model that defines the position of helix 1, the N-terminal 
strap, and the C-terminus, all of which are involved in actin bundling (6, 103, 127), would 
provide clues as to how these components may be involved in forming the interface for the 
Vt dimer. Additionally, recent improvements in cryo-EM data collection should make direct 
observation of the crosslinked F-actin structure more tractable.  Single-particle analysis 
techniques, which provide the highest-resolution cryo-EM models, are not applicable to such 
structures. However, cryo-EM tomography would be applicable. Normally a low-resolution 
technique, application of the best cameras (165), direct electron detectors (166), and 
averaging, in conjunction with the high-resolution model of the binding interaction, cryo-
EM tomography may be applicable in developing a medium-resolution (~15-30 Å) model for 
the Vt:Vt dimer bound to F-actin (167). At this resolution, sidechains and secondary 
structure would not be resolved. However, using the binding model, flexible fitting, and 
computational modeling, a strong model could be developed that makes testable predictions 
about the Vt dimer interface. 
As improvements in cryo-EM technology hold great promise for better models of 
Vt:actin interactions, improvements in developing lipid structures for structural biology 
applications now make a much better Vt:PIP2 model possible. The development of smaller 
nanodiscs for use in solution NMR (168) has great promise for revealing how Vt binds, since 
its backbone has already been assigned. Nanodiscs can also be used with cryo-EM to 
visualize protein:lipid interactions (169). While cryo-EM would not reveal exactly what part 
of Vt binds the PIP2 headgroup, it would shed light on how Vt associates with the lipid 
bilayer. Additionally, the use of the lipid cubic phase in generating crystals of protein:lipid 
complexes provides another exciting structural technique (170) that may show how Vt binds 
PIP2 at a lipid membrane and reveal the conformational changes that take place upon PIP2-
binding (10). The beauty of these technologies is that all of them provide high-resolution 
structures of protein:lipid complexes in the context of a lipid bilayer, a more biologically 
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relevant interaction than with a short-chain phospholipid molecule. With such a wide variety 
of techniques available, it will be only a matter of time before a better high-resolution model 
of the Vt:PIP2 interaction is published. 
These pending improvements in the structural models of Vt bound to two of its ligands 
will provide key tools by allowing for rational design of vinculin mutants with defects for 
specific interactions. These tools can then be used to answering the more important 
question: how do vinculin’s specific interactions drive specific biological responses? Work 
from the Adamson lab in generating vinculin knockout mice and embryonic fibroblasts 
provided the foundational tools and understanding for vinculin’s biological function (8, 9). 
However, limited funding and the sheer number of vinculin’s binding partners continue to 
make deciphering the specifics of vinculin function extremely difficult. In addition to these 
challenges, vinculin is posttranslationally modified at many sites, and these modifications 
can have different regulatory functions when vinculin is localized to different structures 
(171). With this many variables, generating a rigorous model to bridge the gap from 
biochemistry to biology remains a distant goal. 
Yet, despite the numerous challenges, much of the foundation for addressing this gap 
in our knowledge is in place. The structural biology techniques that will provide high-
resolution models for vinculin interactions with binding partners are now being established. 
Fluorescent microscopy techniques have improved such that protein localization within an 
adhesive structure can be determined (55). Förster resonance energy transfer (FRET) 
sensors to measure vinculin activation (172) and tension across vinculin (173) within cells 
now exist and can provide key readouts on vinculin activity. Advances in traction force 
microscopy (174) have pushed the technology into three dimensions, providing better 
biological readouts on cellular behavior. Coupling these improvements with more traditional 
techniques, including FRAP, immunoprecipitation, cellular migration assays, and live-cell 
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fluorescent imaging generates a substantial toolbox with which scientists can probe the 
consequences of individual vinculin:ligand interactions.  
The remaining challenges, therefore, are less technical and more nuanced. The amount of 
time and effort required to evaluate so many different combinations of ligands and 
posttranslational modifications is daunting. The best way to address this challenge, short of 
a National Institutes of Health mandate, is to leverage the strengths of different labs in 
collaborative projects. This has begun to happen with greater frequency, as evidenced by 
many recent publications that employ biochemical, biophysical, and cell biology techniques 
to address vinculin function (40, 103, 115, 123, 171, 175). Such collaboration is vital to 
understanding vinculin function. More of these partnerships will arise in the coming years, 
especially if the current collaborations continue to be as productive and influential. This 
more complete understanding of vinculin is required to address the conflicting reports of 
vinculin’s role in cancer progression.  
 
In addition to the structural work described in this thesis, I have also reported on 
probing the conformational dynamics of  Vt. Studying these dynamics further inform the 
field in how proteins move and provide valuable information for testing of molecular 
dynamics simulations. In the case of vinculin, these conformational dynamics also play an 
essential role in its biological function. They allow vinculin to crosslink actin filaments (120), 
which is essential for mechanotransduction (6). Additionally, conformational changes take 
place upon binding to PIP2 (10), which may play a role in allowing vinculin to oligomerize at 
the plasma membrane (40). However, connecting Vt dynamics in the absence of ligands to 
these conformational changes is not straightforward and will require further dynamic data 
and a better understanding of the bound conformations.  
If vinculin does play a significant role in cancer development, these conformational 
dynamics may provide a way to target vinculin function. Compounds could be developed to 
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target specific conformations of vinculin, enhancing the signaling response associated with 
that particular conformation or signaling when and where that conformation is present. One 
of the simplest conformations to target would be vinculin in its inactive form. A drug that 
stabilized the Vh:Vt interaction would be able to significantly impair vinculin function. 
Other, more specialized conformations could potentially be targeted to tune vinculin 
function. Such applications are in the distant future, however. Vinculin is ubiquitously 
expressed, so efficient targeting of the drug to cancer cells would be essential to limiting 
negative side effects. Additionally, identifying these conformations and developing 
compounds to target them would require development of high-throughput assays to evaluate 
the conformation being selected for or against.  
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